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Foreword
It is with great pleasure that I introduce Minor Tranquillisers and Sedative Use and Misuse in the West of Ireland.
This is the first in a series of research reports commissioned by the Western Region Drugs Task Force.
The National Drugs Strategy 2001-2008 and Western Region Drugs Strategy 2005-2008 emphasised the
importance of research. It is the first step in the development of services, establishment of best practice
guideline, and assists in ensuring value for money.
The aim of the National Drugs Strategy is “to significantly reduce the harm caused to individuals and society by
the misuse of drugs and alcohol through a concerted focus on supply reduction, prevention, treatment and research”
(Shared Solutions, 2005).
In order to significantly reduce harm we must first identify the causes. This report focuses primarily on
the three parties involved in a prescription: the Prescriber, the Pharmacist and the Patient; and brings
together perspectives from service providers and service users aswell as official statistical sources. This
document contains disquieting evidence of the misuse of minor tranquillisers and sedatives and of poor
prescribing patterns. However, it is important to note that many GPs do adhere to the Good Practice
Prescribing Guidelines for Clinicians, issued in 2002. This report also makes important observations in
relation to the monitoring systems currently in place.
On behalf of the Western Region Drugs Task Force my thanks to Kealan Flynn of iWrite Consulting for
his dedication. He has worked tirelessly on this report and his effort is reflected in the pages that follow.
His findings will encourage much needed debate and I trust they will influence members of the medical
profession when prescribing minor tranquillisers and sedatives in the future. Thanks also to Dr Saoirse
Nic Gabhainn of the Health Promotion Research Centre, NUI, Galway for her invaluable contribution as
research advisor on all three reports.
I welcome the opportunity to thank John Curran, T.D., Minister of State with responsibility for the National
Drugs Strategy for launching this report; and the Department of Community, Rural, and Gaeltacht Affairs
for funding this research.
A copy of this research report will be distributed to all GPs and Pharmacies in the west of Ireland.
The publication will also be available for download from www.wrdtf.ie.
As Shared Solutions states: “No one agency can tackle all drug-related problems on its own, but working together
we can hopefully reduce the harmful impact of substance misuse”.
This document is a significant first step in achieving our goal.
Orla Irwin
Co-ordinator
Western Region Drugs Task Force
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6DDD: Defined Daily Dose - an international measure of drug utilisation pioneered by the World Health
Organisation. It is the assumed average maintenance dose per day for a drug used for its main indication
in adults. DDD is seen as a technical value, a close approximation of the average of the actually used
dosages.
DPS: Drug Payment Scheme - provides a range of healthcare services at a reduced rate to those who are
eligible.
GMS: General Medical Service (Medical Card) - scheme that provides a range of healthcare services free
of charge to those who are eligible.
LTI: Long Term Illness  - scheme that provides certain healthcare services free of charge to individuals with
designated long-term illnesses and conditions e.g cystic fibrosis, diabetes and epilepsy, among others.
Minor Tranquillisers and Sedatives: Term used throughout this report to refer to the class of psychoactive
substances that includes benzodiazepines and related drugs. Described in Martindale, the international
drug reference book, as anxiolytic sedatives (formerly minor tranquillisers), which have been used in the
management of anxiety disorders; and drugs used to produce sleep (hypnotics). 
PCRS: Primary Care Reimbursement Service - the arm of the Health Service Executive which processes
payments to all GPs, Dentists, Pharmacists and other healthcare professionals who provide free or
reduced cost services to the public.
Glossary
7Minor Tranquillisers and Sedatives
- Benefits and Problems1
8Introduction
Benzodiazepines and non-benzodiazepine
hypnotics, or minor tranquillisers and sedatives as
they are referred to throughout this report, are a
class of psychoactive drugs with hypnotic and
sedative effects. They have powerful, proven
benefits when taken in small doses for a limited
time. The problem is that many people may have
become addicted because they have been
receiving and taking them for longer or at a higher
dose than they should, perhaps for months or
years. In 2002, official guidelines were issued to
encourage correct usage and good prescribing,
and to cut down on misuse and poor prescribing.
However, there is clear evidence in the west of
Ireland of incorrect use and prescribing, especially
for women, older people and people on low
incomes.
This first chapter presents the findings from the
literature review, which has been put together
following a study of original papers accessed
through respected internet resources like Pub
Med, Medline Plus, ProQuest, Business Source
Premier, the Social Sciences Citation Index, as well
as the salient points from the international drugs
bible, Martindale.1
The first section of this chapter gives a general
overview of the history and impact of minor
tranquillisers and sedatives. The second outlines
the questions this research seeks to answer. The
third describes the current position in terms of
legislation and regulation, and outlines the main
points from the official guidelines on the correct
usage and prescribing of minor tranquillisers and
sedatives. The final section summarises the
findings of international studies on the misuse of
these drugs.
History and Impact
Benzodiazepines are psychoactive drugs that are
used to aid sleep, reduce anxiety and induce
feelings of relaxation. They are widely prescribed
but widely misused. Along with alcohol and
barbiturates, they act primarily on the central
nervous system, affecting brain function and
altering an individual’s perception, mood,
consciousness and behaviour.
According to Black’s Medical Dictionary,
benzodiazepines make up “a large family of drugs
used as hypnotics, anxiolytics, minor tranquillisers,
anticonvulsants, pre-medication, and for intravenous
sedation … short acting ones are used as hypnotics, longer
acting ones as hypnotics and minor tranquillisers … they
act as a specific nervous system receptor or by potentiating
the action of inhibitory neuro transmitters. They have
advantages over other sedatives by having some
selectivity for anxiety rather than general sedation.”2
Benzodiazepines were first marketed as a safer
alternative to barbiturates, an older class of drugs
that also depressed the central nervous system,
but which had often been linked to accidental
death and deliberate suicide, particularly when
taken with alcohol to bring on sleep. According to
Parrott et al (2004), benzodiazepines do not cause
respiratory slowing and so are far less dangerous
in overdose. This was a key reason why they
replaced barbiturates for relieving anxiety
conditions. Anxiety refers to a broad bundle of
clinical conditions making up between 5% and
10% of psychiatrically diagnosed diseases in the
western world.
The first benzodiazepine was a drug called
Chlordiazepoxide, which is marketed under the
trade name of Librium. When it was studied, it was
found to have sedative, anticonvulsant and
muscle-relaxant effects. Discovered in 1957,
Chlordiazepoxide had “remained untested until a
research chemist chanced upon it while tidying up the
1 Martindale (2002). (33rd Edition). London: Royal Pharmaceutical Society.
2 Black’s Medical Dictionary (1992) (37th Edition). London: A&C Black. p.61.
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laboratory.” 3 Other related drugs followed over the
next two decades; and the benzodiazepines
achieved such worldwide popularity that they
became the most commonly prescribed drugs in
the 1970s and 1980s. By the mid-1980s, there
were 17 benzodiazepines on the market. A decade
previously, two brands - Librium and Valium -
accounted for half of all psychoactive drug
prescriptions dispensed in the USA; and it was
estimated that half a billion people worldwide had
taken a benzodiazepine.
It has since been found that regular use of
benzodiazepines leads to loss of therapeutic
benefit, increased dosage, unpleasant withdrawal
symptoms and drug dependence. “Even small doses
[impair] the ability of pilots to fly aircraft and motorists to
drive cars … [their] … disinhibitory effects also mean
that they are associated with antisocial acts, including
physical and verbal aggression and numerous types of
crime.” 4
Salzman (1999) advises, however, that worries
about safety and dependence should not take 
from their role and value: “Benzodiazepines are neither
a panacea nor a curse”, he says. “It is unfortunate that
legitimate therapeutic use is sometimes obscured by
controversy over issues of safety and dependence. Despite
adverse effects, dependence and inappropriate use,
benzodiazepines remain an appropriate pharmacological
treatment for anxiety, one of the most prevalent forms of
human suffering.” 5
Ireland has neither been isolated from nor immune
to developments elsewhere. This research is
intended as a contribution to the existing store of
knowledge about the use of minor tranquillisers
and sedatives and their benefits and drawbacks.
The problem is not correct use for the right
reasons, but the problems that can and do occur
when they are used inappropriately.
It is important in this context to acknowledge that
there are three parties to every prescription for a
minor tranquilliser or sedative; and in situations
where usage may be inappropriate, that each is
part of the problem and must be part of the
solution. There is the patient who obtains the
inappropriate prescription, the prescriber who
writes it, and the pharmacist who dispenses it. We
should expect the patient to be the least and the
prescriber and the pharmacist the most powerful in
this relationship. This raises the key question of
who should act in order to prevent or minimise
inappropriate use and prescribing; and the related
question of what assistance they may need to act
appropriately.
The elephant in the room is the state-funded drug
reimbursement regime, which pays a professional
fee to both the doctor and the pharmacist for every
prescription validly written, and validly dispensed,
but which appears by its very nature to be
singularly ill-equipped to deal with inappropriate
prescribing and dispensing. Exchequer spending
on minor tranquillisers and sedatives in Ireland has
almost doubled in the space of  eight years - from
€14.01m in 2000 to €26.42m in 2007. The
cumulative spend from the public purse on drug
costs and related professional fees in respect of
these drugs stands at €168.9m over the whole
period; and the professional fees paid on the two
main drug refund schemes have now begun to
exceed the ingredient costs of the drugs.6
But, if the elephant in the room is the drug cost
reimbursement regime, the absent friend has to be
the electronic monitoring system that would alert
prescribers, pharmacists and public health
authorities in ‘real time’ to be vigilant at all times in
the interests of the individual and the community as
a whole.
3 Parrott A, Morinan A, Moss M and Scholey A (2004): Understanding Drugs and Behaviour, p.128. West Sussex,
England: John Wiley & Sons.
4 Parrott (2004): op. cit. p.120.
5 Salzman, C. (1999). An 87 year-old woman taking a benzodiazepine. Journal of the American Medical
Association, 281, 1121-1125.
6 Data Source: Primary Care Reimbursement Service, Health Service Executive.
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The Report of the Benzodiazepine Committee
(2002) divided the benzodiazepines into two broad
but not mutually exclusive categories:
a) Anxiolytics i.e., anxiety reducing drugs e.g.,
Diazepam, Alprazolam, Clobazam,
Bromazepam, Chlordiazepoxide, and
Chlorazepate.
b) Hypnotics i.e., sleep-inducing drugs e.g.,
Flunitrazepam, Flurazepam, Loprazolam,
Lormetazepam, Nitrazepam, and Temazepam.
A number of related drugs – the non-
benzodiazepine hypnotics or second-generation
anxiolytics – were also included in that report. The
‘Z drugs’ – Zaleplon, Zolpidem and Zopiclone –
have a different make-up to the benzodiazepines,
but act similarly. They have the same downsides
i.e., tolerance, dependence, withdrawal symptoms
and addiction.7
In essence, hypnotics are used to relieve insomnia,
but only after the underlying causes have been
discovered and treated; and the professional
advice is that long-term use, especially of
benzodiazepines, should be avoided. Anxiolytics,
in contrast, are used for short-term relief (two to
four weeks only) of anxiety that is severe, disabling
or causing unacceptable distress to an individual.
Where the person has chronic anxiety (i.e., lasting
for more than four weeks), it may be more
appropriate to use an antidepressant.8
The Benzodiazepine Committee stated that, when
used correctly, benzodiazepines are beneficial for
a wide range of clinical conditions, like anxiety,
insomnia, panic, epilepsy, and pre-surgical stress.
It stated that nearly all of their downsides come
from long-term use, and that tolerance,
dependence and withdrawal effects can be
seriously debilitating.9
However, the report also noted that, while the major
medical bodies had advised that benzodiazepines
should not be prescribed for more than two to four
weeks, there was evidence that there were still
many long-term prescribed users, who appeared
to be receiving little advice or support from their
doctors; and some medical practitioners who were
not well informed about benzodiazepine
withdrawal symptoms or methods of withdrawal.10
Examining the prescribing patterns for medical
card holders, who numbered about one-third of the
population at the time, the Benzodiazepine
Committee found that 1 in 10 people overall and 1
in 5 of people over 60 were prescribed minor
tranquillisers and sedatives. It also found that the
standard prescription quantity appeared to be for a
month’s supply, from which it concluded that
prescribing in many cases was both routine and
excessive.
Benzodiazepine Committee - Good Practice Prescrbing Guidelines
7 See Martindale (2002) op. cit. 649-714 for detailed scientific information on the evidence.
8 British National Formulary – accessed through NHS Scotland Information Services Division, at
http://isd.scot.nhs.uk/isd/information-and-statistics.jsp (Accessed 8 May 2008).
9 DOHC (2002). Report of the Benzodiazepine Committee. Dublin: Department of Health and Children.
10 In January 2006, the Minister for Health and Children informed Dail Eireann that good practice guidelines on the
prescribing of benzodiazepines had been circulated widely to Health Service Executive areas and to General
Practitioners throughout the country. She added that arrangements had been put in place by HSE treatment clinics
and GPs to reduce sources of multi-prescribing to known drug users; and that similar, less detailed, requirements
were laid down for prescriptions for medicinal products other than controlled drugs.
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In Ireland, only doctors and dentists may prescribe
minor tranquillisers and sedatives, and only
pharmacists may dispense them.11 Under the
Medicinal Products Regulations, there are a
number of control schedules. The first schedule
lists all of the medicines for which a prescription is
required. The schedule has three categories – S1A,
S1B and S1C. A prescription for an S1A medicine,
which includes minor tranquillisers and sedatives,
may be dispensed only once, unless the prescriber
states it can be repeated. However, it is not enough
for the prescriber to write the word ‘repeat’: specific
dosages and either the number of occasions or the
intervals of supply (e.g., weekly or monthly) must
be clearly stated and cannot exceed six months.12
A core part of the regulatory role of the
Pharmaceutical Society of Ireland is about
ensuring that dispensing practices comply with
these requirements. Inspectors must discuss with a
pharmacist at the time of an inspection if they
suspect incorrect prescribing or ordering of
controlled drugs. Inspectors maintain a regular
dialogue with the HSE’s primary care units13, who
maintain, or used to maintain, a data store on
prescribing by GPs. This was introduced under the
drug budgeting scheme.
When the Benzodiazepine Committee was
proposing changes for promoting rational
prescribing, it was considered that one use of the
data store could be in ‘red flagging’ prescribing
patterns that were out of kilter with a regional norm.
This could then be the trigger for a designated
person, perhaps another medical practitioner, to
offer advice and support to the doctor concerned.14
However, the data store does not appear to have
been used in this way at any time. It may thus be
argued that this makes it harder to identify,
investigate and deal effectively with those who
prescribe poorly; harder to develop a system of
medical audit or peer review of prescribing
practices; and harder for Primary Care Units to be
proactive at all times in providing advice and
support to GPs on best prescribing practice. But
though it may be harder, it is not impossible.
The main initiatives for promoting good prescribing
practice in the region have been the guidelines
issued by the Department of Health and Children,
and various circulars from the HSE’s Primary Care
Unit. In addition, various initiatives have been taken
by the Irish College of General Practitioners,
including prescribing road shows, substance
misuse programmes, and continuing medical
education.15 However the evidence of this report is
that on the whole these actions have had little
impact, certainly not in this region.
Legislation and Regulation
11 Medicinal Products Regulations 2003-2007 and Misuse of Drugs Regulations 1988.
12 National Medicines Information Centre (2004). Medication Safety, 10(6).
13 Personal Communication from the Pharmaceutical Society of Ireland.
14 Personal Communication from the Irish College of General Practitioners.
15 Personal Communication from the Irish College of General Practitioners.
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Literature Review
According to Julien (2001), the major use of
benzodiazepines in a clinical setting is for “anxiety
that is so debilitating that the patient’s lifestyle, work and
interpersonal relationships are severely hampered.” 16
Cape and others (2002) document their effects as
including:
• Tolerance
• Dependence
• Emotional blunting
• Drowsiness
• Lethargy
• Motor in-coordination
• Decreased reaction time
• Muscle weakness
• Confusion
• Vertigo
• Headache
• Depression
• Blurred vision
• Slurred speech
• Paradoxical euphoria, excitement,
restlessness, hypomania, and feelings of
invisibility, invincibility and invulnerability.17
However, non-medical usage is common. In the
USA, nearly 10% of those with non-medical use
meet the criteria for misuse / dependence.18 In
Dublin, minor tranquillisers and sedatives have
been identified as the most popular drugs of
misuse among clients on methadone maintenance.
Restrictions on prescribing of Zopiclone to drug
misusers have been recommended.19 The issue of
Zopiclone dependence has also been
documented in case reports, clinical studies and
literature review; and an increased risk of misuse
has been documented for patients with a history of
dependence or misuse, and for patients with
psychiatric illnesses.20 The general issues of
dependence, withdrawal and misuse in respect of
minor tranquillisers and sedatives21 are
documented extensively in the literature, and in
acclaimed international drug reference books like
Martindale.22
Martindale notes that dependence may develop
after regular use of benzodiazepines even in
therapeutic doses for short periods. While
dependence cannot be predicted, risk factors
include high doses, regular continuous use, use of
short-acting drugs, use in patients with dependent
personality characteristics or a history of drug 
or alcohol dependence, and the development 
of tolerance.
Symptoms of withdrawal include:
• Anxiety
• Headache
• Dizziness
• Tinnitus
• Irritability
• Perspiration
• Muscle twitching
• Hallucinations
• Convulsions
• Psychosis
It has been found that short- or long-term patterns
of benzodiazepine misuse are associated with
excess sedation, cognitive impairment and
increased risk of accidents.23 Studies of polydrug
consumption have confirmed that benzodiazepine
misuse is widespread among heroin users, and
16 Julien, R.M. (2001). A Primer of Drug Addiction. New York: Worth. p.163.
17 Cape, G., Hulse, G., Robinson, G., Mclean, S., Saunders, J., Young, R. & Martin, J. (2002). Sedative Hypnotics. In G. Hulse, J. White &
G. Cape (eds.) Management of Alcohol and Drug Problems. Melbourne: Oxford University Press.
18 Becker, W.C., Fiellin, D.A. & Desai, R.A. (2007). Non-medical use, abuse and dependence on sedatives and tranquillizers among US
adults: psychiatric and socio-demographic correlates. Drug and Alcohol Dependence, 90(2-3), 280-287.
19 Bannan, N., Rooney, S. & O’Connor, J. (2007). Zopiclone misuse: an update from Dublin. Drug and Alcohol Review, 26(1), 83-85.
20 Haasen, C., Mueller-Thomson, T., Fink, T., Bussopulos, A. & Reimer, J. (2005). Zopiclone dependence after insomnia related to torticollis.
International Journal of Neuropsychopharmacology, 8(2), 309-310.
21 Jones and Sullivan (1998) find that zopiclone appears to cause dependence with long-term use. Others suggest the risk of dependence
on zopiclone may be greater in those with dependent personalities. See BMJ (1998) 316, p.117 and BMJ (1998) 317, p.146.
22 See Martindale (1992) op. cit. ‘Anxiolytic Sedatives, Hypnotics and Antipsychotics’, pp. 649-714 for a detailed discussion of and
specific references to individual minor tranquillisers and sedatives.
23 Oster, G., Huse, D.M., Adams, S.F., Imbimbo, J. & Russell, M.W. (1990) benzodiazepine minor tranquillisers and the risk of accidental injury.
American Journal of Public Health, 80, 1467-1470.
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that when both are taken concurrently, there are
numerous harmful consequences, including higher
levels of risk-taking, fatal overdose, poorer health
and psychological functioning.24 25 26 Concerns
about the injection of Temazepam from gel
capsules among heroin users, led to the
withdrawal of Temazepam gel capsules in
Australia.27 When taken together with Methadone,
benzodiazepines are a major risk factor for
premature death.28 29
Benzodiazepines are of limited therapeutic benefit
for older people and increase the risk of adverse
events, such as falls and fractures.30 31 32 One
French study has found that benzodiazepine use
could be held responsible for almost 20,000
injurious falls and nearly 1,800 deaths.33 In the
USA, however, the incidence of hip fractures in
older people did not decline following new
surveillance rules obliging prescribers to notify the
authorities of each prescription they issued for a
benzodiazepine.34 While the limited availability of
alternative therapies is identified as a contributing
factor to continuing overuse35 there is also
evidence that tapering-off and/or group
behavioural therapy are cost-effective.36
Significantly, dependence and withdrawal effects
can occur within weeks, even when patients are
receiving short-term therapy and/or the
recommended dose.37 38 According to Julien
(2001), “early withdrawal signs include a return (and
possible intensification) of the anxiety state for which the
drug was originally given. Rebound increases in insomnia,
restlessness, agitation, irritability and unpleasant dreams
gradually appear. In rare instances, hallucinations,
psychoses and seizures have been reported. Most of these
withdrawal symptoms subside within one to four weeks.”
39 40
People with a history of drug or alcohol misuse are
most likely to misuse benzodiazepines, usually as
part of a pattern of multiple drug misuse.41 In the
USA, for example, Alprazolam is used
recreationally in repeated doses as an intoxicant,
or in combination with alcohol and painkillers, or as
a way to come down from a cocaine ‘high’.42
Benzodiazepines are more likely to be prescribed
for women than men, and for those for whom levels
of material deprivation are greatest. In addition, it
has been reported that the pressures to which
doctors may be subjected mean that good
prescribing guidelines tend to be honoured more in
24 Hando, J., Hall, W., Rutter, S. & Dolan, K. (1998). Current State
of Research on Illicit Drugs in Australia. Sydney: University of
New South Wales.
25 Australian Government’s Institute of Criminology (2007).
Benzodiazepine use and harms among police detainees in
Australia. www.aic.gov.au/media/2007/20071614.html (Accessed
21 April 2008).
26 Darke, S., Degenhardt, L. & Mattick, R. (2007). Mortality
Amongst Illicit Drug Users: Epidemiology, Causes and
Intervention. Cambridge: Cambridge University Press.
27 Ross, J. (2007). Illicit Drug Use in Australia: Epidemiology, Use
Patterns and Associated Harm (2nd Edition). Sydney: University
of New South Wales.
28 Caplehorn, J. & Drummer, O. (2002). Fatal methadone toxicity:
signs and circumstances, and the role of benzodiazepines.
Australian & New Zealand Journal of Public Health, 26(4), 358-
363.
29 Ernst, E., Bartu, A., Popescu, A., Ilett, K., Hansson, R. &
Plumley, N. (2002). Methadone-related deaths in western
Australia 1993-99. Australian & New Zealand Journal of Public
Health, 26(4), 364-370.
30 Leipzig, R.M., Cumming, R.G. & Tinetti, M.E. (1999). Drugs and
falls in older people: a systematic review and meta-analysis.
Journal of the American Geriatric Society, 47, 30-39.
31 Cooper, J.W. (1993). Use of anxiolytics and hypnotic drugs.
Nursing Homes: Long-Term Care Management, 42(6), 37-39.
32 Windle, A., Elliot, E., Duszynski, K. & Moore, V. (2007).
Benzodiazepine prescribing in elderly Australian general
practice patients. Australian & New Zealand Journal of Public
Health, 31(4), 379-381.
33 Pariente, A., Dartigues, J.F., Benichou, J., Letenneur, L., Moore,
N. & Fourrier-Reglat, A. (2008). Benzodiazepines and injurious
falls in community dwelling elders. Drugs and Aging, 25(1), 61-
70.
34 Quoted in BMJ (2007) 334, pp. 282-283.
35 Windle et al. (2007). op. cit.
36 Oudevoshaar, R., Krabbe, P., Gorgels, W., Adang, E., Val
Balkom, A., Van De Lisdonk, E. & Zitman, F (2006). Tapering off
benzodiazepines in long-term users: an economic evaluation.
PharmacoEconomics, 24(7), 683-695.
37 Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M,
and Sykora K: ‘Withdrawal reaction after long-term therapeutic
use of benzodiazepines’. New England Journal of Medicine
1986; 315: 854-859.
38 McKinnon, G.L. & Parker, W.A. (1982). Benzodiazepine
withdrawal syndrome – a literature review and evaluation.
American Journal Drug Alcohol Abuse, 9(1), 19-33.
39 Julien (2001). op. cit. p.165.
40 The issue of rebound insomnia from long-term use of
benzodiazepines has also been documented briefly in Zablocki,
E. (2006), Most insomnia medication effective for short-term use’,
Managed Healthcare Executive, 16(4), 52-53.
41 Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W. &
Gilman, A.G. (1996). Goodman and Gilman’s Pharmacological
Basis of Therapeutics. New York: McGraw-Hill. pp. 365-367.
42 A very serious problem, Newsweek, 139(6), 2 November 2002.
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the breach than in the observance, the
consequences of which include massive over-
supply to, and associated misuse, in the
community.43 44
In short, the everyday realities in a busy General
Practice make it easy for a determined patient to
pressure a doctor into writing a prescription they
might prefer not to give; and more likely that a
doctor, who may have a long line of patients to see
in a short time, will simply decide that discussion
and debate with a particular patient is unlikely to
have any immediate benefit.
The impact of the problem of benzodiazepine
misuse on specific population groups has been
tracked in successive national drug prevalence
surveys. During 2002-2003, sedatives, minor
tranquillisers or antidepressants had been
prescribed to 12% of people aged between 15 and
64, but to a higher proportion of people in a difficult
or disadvantaged life situation:
• 25% of people on long-term state benefits
• 23% of those not in paid employment
• 26% of separated people
• 42% of divorced people
• 28% of widowed people
Prisons have significant problems with minor
tranquillisers and sedatives. A recent issue of the
magazine ‘DrugNet’ presented statistics from the
Prison Service in 2007, which found that in
Castlerea Prison, County Roscommon, of the 92
drug tests carried out for alcohol, amphetamines,
benzodiazepines, cannabis and cocaine, a total of
17, or 19% of all positive tests, were for
benzodiazepines, higher than any other drug.45
In the general population, women (15%) are much
more likely than men (9%) to have taken minor
tranquillisers and sedatives.46 This gender bias is
also evident in other countries. In Canada, for
example, women are twice as likely to have
benzodiazepines prescribed for non-clinical
symptoms, like stress, acute or chronic illness,
physical pain, or adjustment to a major life change,
and to have them prescribed for longer periods.47
Research in the Dublin suburb of Ballymun also
documents a gender bias in prescribing for
women, a level of benzodiazepine prescribing that
may be notably higher than the national level, and
a relationship between socio-economic
disadvantage and use of benzodiazepines. It
concludes there is a significant supply of
benzodiazepines in the community from legitimate
prescriptions, that this is commonplace and
culturally accepted, and plays a part in the
development of substance misuse problems.48
In Australia, the experience is that the majority of
drugs being diverted to the illicit market are from
the domestic rather than the international
pharmaceutical trade; and that doctor shopping,
pharmacy hopping, theft or diversion from
wholesalers and retailers, and diversion from
treatment programmes, are major supply drivers
for the illicit market.49
43 Quigley, P., Usher, C., Bennett, K. & Feely, J. (2006). Socioeconomic influences on benzodiazepine consumption in
an Irish region. European Addiction Research, 12(3), 145-150.
44 Benzodiazepines are commonly prescribed to Dublin’s disadvantaged. Sunday Times, 9 July 2006.
45 Health Research Board (2008). DrugNet Ireland, 26, Summer.
46 National Advisory Committee on Drugs (2007). Drug Use in Ireland and Northern Ireland: The 2002/2003 Drug
Prevalence Survey – Sedatives, Minor Tranquillisers or Antidepressants.
http://www.nacd.ie/publications/Bulletin6_STAD.pdf (Accessed 15 April 2008).
47 Cormier, R.A., Dell, C.A. & Poole, N. (2004). Women and Substance Abuse Problems. BMC Women’s Health, 4(1).
http://www.phac-aspc.gc.ca/publicat/whsr-rssf/pdf/WHSR_Chap_7_e.pdf (Accessed 15 April 2008).
48 Ballymun Youth Action Project (2004). Benzodiazepines – Whose Little Helper?
http://www.nacd.ie/publications/BYAPbenzosReoprt.pdf (Accessed 15 April 2008).
49 Nicholas, R. (2002). The Diversion of Pharmaceutical Drugs onto the Illicit Market. Australasian Centre for Policing
Research. http://www.acpr.gov.au/pdf/drugs/Diversion%20of%20pharm.pdf (Accessed 22 April 2008)
In recent years, the problem of benzodiazepine
misuse appears to have been greater outside than
inside the capital. In 2002, in the old ERHA, which
served Dublin, Kildare and Wicklow,
benzodiazepines were the main problem drug
reported in 0.7%, or 42 out of 6,248 cases. In the
rest of the country, this figure was 2.7% or 64 out of
2,328 cases.50 By 2005, for the whole country,
benzodiazepines were the main problem drug in
1.5% or 77 cases of 12,400 problem drug users
who were treated that year.51
The Western Region Drugs Task Force has noted
that the relatively low number of polydrug and
opiate misusers in Galway, Mayo and Roscommon
means that if there is a benzodiazepine misuse
problem of any notable size, it is more likely to be
found in the general population.52
Without doubt, there is indeed such a problem
within the general population. A study by the
National Institute of Pharmacoeconomics, which
analysed prescription data gathered by the PCRS
in 2004, found that for all health regions, between
38% and 49% of medical card patients prescribed
benzodiazepines received this medication for more
than four weeks. In the case of counties Galway,
Mayo and Roscommon, 16% were receiving
maintenance benzodiazepine therapy for more
than three months. A similar pattern was found with
private patients. These results clearly show that the
prescribing of benzodiazepines for more than four
weeks continues in contravention of the best
practice prescribing guidelines.53
Some experts have attributed the continued
escalation in minor tranquilliser and sedative
prescribing to an almost complete absence of
counselling facilities for medical card patients.
Because of this, they say, doctors have little option
except to prescribe extensively and perhaps
inappropriately.54
Concluding Comments
• Benzodiazepines and non-benzodiazepine
hypnotics, or minor tranquillisers and sedatives
as they are more commonly known, are
psychoactive drugs that have proven,
documented therapeutic benefits when taken
as recommended.
• However, despite the documented evidence of
health risks from incorrect usage, particularly
the dangers of tolerance and dependence,
they continue to be prescribed and used
extensively. In Ireland, spending on minor
tranquillisers and sedatives through the main
community drug refund schemes has doubled
from €14.01m in 2000 to €26.42m in 2007, with
total spend for the period standing at €168.9m.
• The Department of Health and Children issued
good practice prescribing guidelines for
clinicians in 2002 to encourage more rational
usage and prescribing. The key questions for
this study are whether these had any impact, if
so for how long, if not which population groups
are being adversely affected, and what would
be the right steps to remedy the problem.
50 DCRGA (2005). Mid-Term Review of the National Drugs Strategy 2001-2008: Report of the Steering Group. Dublin:
Department of Community, Rural and Gaeltacht Affairs.
51 DCRGA (2007). Report of the Working Group on Drugs Rehabilitation, National Drugs Strategy 2001-2008. Dublin:
Department of Community, Rural and Gaeltacht Affairs.
52 WRDTF (2006). Shared Solutions – First Strategic Plan of the Western Region Drugs Task Force. Galway: Western
Region Drugs Task Force.
53 National Centre for Pharmacoeconomics (2006). Utilisation of benzodiazepines on the General Medical Services
(GMS) Scheme, 2004. www.ncpe.ie (Accessed 8 May 2008).
54 Lack of counsellors leads to over-reliance on benzodiazepine prescription. Sunday Independent, 12 Dec 2004.
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In Ireland, spending on minor
tranquillisers and sedatives
through the main community
drug refund schemes has
doubled from €14.01m in 2000 to
€26.42m in 2007
17
Statistical Analysis2
18
Introduction
We noted previously that the relatively low number of
polydrug and opiate misusers in the western region
would tend to suggest that if there is a
benzodiazepine misuse problem of any notable
size, it is more likely to be in the general population.55
We also noted the findings of the last significant
study of prescribing, carried by the National Centre
for Pharmacoeconomics (NCPE), which found that
16% of people with medical cards in the western
region were being maintained on minor tranquillisers
and sedatives for longer than three months. A similar
pattern was found with private patients,
demonstrating that prescribing for longer than four
weeks is the norm.56
The NCPE study was limited in its scope in the
sense that it analysed one year of prescription
records. We have looked back over a longer
timeframe, starting in January 2000, three years
before the guidelines, and finishing five years after,
in December 2007. The Primary Care
Reimbursement Service supplied these records (this
is the drug cost reimbursement arm of the Health
Service Executive).
We procured electronic spreadsheets of the
prescription records held by the PCRS under the
three main community drug refund schemes, for
counties Galway, Mayo and Roscommon for the
period 2000-2007. Each record has a standard set
of fields: the patient's number (but not their name),
age, gender, drug prescribed e.g. Diazepam,
strength or form, quantity supplied and number of
prescriptions that year. The GMS files have one extra
field: the prescriber number (not their name).
We also examined figures from the Health Research
Board, which maintains a national database on
those presenting for treatment for problem drug use.
The National Drug Treatment Reporting System
paints an interesting picture of those coming forward
– their number, age, gender, nationality, place of
residence, accommodation and employment status,
drugs taken, and whether this is a major or minor
problem drug.
The most remarkable contrast between the HRB and
HSE data relating to the three western counties is
the small number presenting for treatment for
addiction by comparison with the much larger
number taking minor tranquillisers and sedatives.
Between 2001 and 2006, just 114 clients residing in
the HSE Western Area sought treatment where
minor tranquillisers and sedatives were a problem
drug. According to the HSE’s prescription records,
however, slightly less than 90,000 individuals were
prescribed them from 2000 to 2007, many on a
repeat basis. In other words, the high prescription
rates and the low levels of treatment must mean
there is substantial unmet treatment need, a lack of
a continuum of supports, and a major hidden
problem of prescription drug addiction in the region.
HRB Data: Problem Use of Minor
Tranquillisers and Sedatives
The Health Research Board has supplied
aggregated data compiled through statistical
returns made by certain healthcare professionals
working in the field of addiction. These include
Level 1 GPs (these are doctors working in the
community who have specific training, and
authorisation to prescribe Methadone), all
Community Substance Misuse Counsellors,
Galway Methadone Clinic, Coolmine Therapeutic
Community, Rutland Centre and Mater Dei Teen
Counselling. All submit quarterly figures to the HRB
on a standardised reporting form.
It should be borne in mind that the figures that
follow give only a partial picture of the overall
picture of addiction. The reason is that particular
service providers have commenced making
statistical returns at different times. The HSE Drug
Service and others, for example, have been
making returns for most or all of the period, but the
Addiction Service in HSE Mental Health only began
making returns for the first time in 2008. In addition,
the general GP population does not make returns,
yet it is in general practice that a potential
addiction may first become apparent.
55 Western Region Drugs Task Force (2006): Shared Solutions, op. cit.
56 National Centre for Pharmacoeconomics (2006): ‘Utilisation of benzodiazepines on the General Medical Services
(GMS) Scheme, 2004’ www.ncpe.ie (Accessed 8 May 2008).
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In Ireland, a total of 67,266 cases reported entering
treatment for drug and alcohol problem use
between 2001 and 2006. Of these, 973 were
residing in the HSE Western Area i.e. in Galway,
Mayo and Roscommon. Among that national figure,
a total of 11,769 or 17.5% reported benzodiazepine
as part of their current problem drug use. Just 114
(1%) were residing in the HSE Western Area at that
time. Of these 114 cases, only 9 reported that
benzodiazepine was the main problem drug; in all of
the others, it was not the main problem drug. Those
114 benzodiazepine cases represent 11.7% of all
cases residing in the HSE West Area entering
treatment for drug and alcohol problem use
between 2001 and 2006.
In essence, less than 1 in 5 of all those entering
treatment nationally did so because
benzodiazepines were part of their problem drug
use. Only 1 in 100 of those with problem
benzodiazepine use were residing in the HSE
Western Area at that time; and less than 1 in 10 of
those reported benzodiazepine as their main
problem drug. In other words, very few people from
the three counties enter treatment for
benzodiazepine problem use; and even fewer
regard benzodiazepine problem use as their main
drug or addiction problem at all. 
According to the HRB data for the 114 cases treated
for benzodiazepine problem use: 
• Counties Galway, Mayo and Roscommon (which
together have slightly less than 10% of the total
population of the State) had slightly less than 1%
of the number of all cases treated where
benzodiazepines were reported as a problem
drug.
• Of this 1%, benzodiazepines were the main
problem drug in nine cases (8%). Opiates were
the main problem in three-quarters.
• Almost 60% of treatment episodes were from
people living in Galway, 26% in Roscommon and
14% in Mayo. This is a particularly interesting
finding, as Mayo has 30% of the region’s
population, while Roscommon has just 14%.
• Diazepam accounted for more than half of
cases where a specific, named minor
tranquilliser or sedative had been identified.
• Almost two-thirds had been treated previously.
• At least two-thirds were male; and nine-tenths
were Irish.
• Almost 85% were aged from 20-39 years;
around 4% were 17 years or less; and less than
2% were over 50 years.
• Nearly 60% lived in stable accommodation;
25% were either homeless or living in
“unstable” accommodation; and over 13%
were institutionalised in a prison or hospital.
• Around three-quarters were unemployed.
• One in five were 14 or younger when they left
school; and half left school at 15 years or older.
• Polydrug use was common. All but three
reported using more than one drug.
• For the nine cases where benzodiazepines
were the main problem drug reported, the
minor problem drug was an opiate in three
cases, cannabis in five, ecstasy in two, and
alcohol in one case.57
• The numbers were evenly split between those
who had injected benzodiazepines and those
who had not; though four out of five said they
had not injected them in the past month.
Before drawing conclusions based on these data,
it is worth noting a key contextual factor. This is that
people who present to a GP with an addiction to
minor tranquillisers and sedatives are more likely to
have a referral, if this is deemed necessary, to the
HSE Mental Health Service (or to a not-for-profit
provider such as Hope House) than they are to the
HSE Drug Service. Again, it’s worth noting that the
Drug Service has been making statistical returns to
the NDTRS for some years, but the Addiction
Service in Mental Health has only recently begun
doing so. Thus, it will be some years yet before a
more complete picture of those coming forward for
treatment can be drawn.
57 Totals under this issue are the total number of cases for which there is at least one additional drug. Each of those
cases may have several additional drugs, hence the total is higher than the number of cases.
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Put another way, the current NDTRS figures relate
to the relatively small number of people accessing
the Drug Service for treatment for the misuse of
illicit drugs, which may include the misuse of minor
tranquillisers and sedatives, and which may or may
not have been prescribed, than they do to the
profile of those in the population at large, who may
be misusing these drugs. That said, there are four
interim conclusions we may draw:
• First, there are very few people presenting for
treatment for an addiction to minor tranquillisers
and sedatives compared to the numbers of
people who have been prescribed them.
• Second, the pre-eminence of Diazepam
suggests it is among the most commonly
prescribed of the minor tranquillisers and
sedatives; and one leaking in significant
amounts to the street.
• Third, males make up the majority of cases,
though as we will see shortly, women get the
most prescriptions.
• Fourth, the majority presenting are under 40,
though as we will also see, most prescriptions
go to people over 40.
HSE Data: Prescriptions for Minor
Tranquillisers and Sedatives
The HSE’s Primary Care Reimbursement Service
(PCRS) is responsible for administering the state-
funded community drug refund schemes. The
three principal schemes together pay some or all of
the cost of the prescription drugs for close to three-
quarters of the State’s population.
We looked at all prescription records for the three
main reimbursement schemes from 2000 to 2007:
General Medical Service for ‘medical card’
patients, Drug Payment Scheme for ‘private’
patients, and Long Term Illness Scheme for people
with certain long-term medical conditions.
The analysis covered just under 90,000 individuals
and just over 1.5 million prescriptions.
The prescription record set permits analysis of a
range of factors, including age, gender,
prescription frequency, drugs dosages and
quantities prescribed, and drug costs and
professional and fees paid. It also enables a fairly
accurate estimate to be made of the proportion of
the population at large that is taking a drug, using
a recognised international measure.
With regard to costs and fees, the record set
reveals that just under €169m was reimbursed
under the three main community drug refund
schemes for the whole country between 2000 and
2007. Almost €90 million of this was for drug
ingredient costs and the remaining €79 million was
for professional  fees. The distribution, by scheme,
of the total spend was 78% in the GMS, 21% on the
DPS and 1% in the LTI. In the GMS, the amount
paid in fees exceeded the cost of drugs for the first
time in 2007. In the DPS, that happened for the first
time in 2006. 
The ‘Defined Daily Dose’ (DDD) is an accepted
international measure of drug utilisation. It is the
assumed average maintenance dose per day for a
drug used for its main indication in adults.
However, since prescribing patterns differ across
countries and the amount prescribed depends on
individual characteristics and pharmacokinetics
(absorption, distribution, metabolism and excretion
of a drug), DDD is seen as a technical value, a
close approximation of the average of the actually
used dosages.58
DDDs are expressed per 1,000 of the population
per day. However, the big three schemes
administered by the PCRS not cover the entire
population, so the unit of expression for the data is
DDDs per 1,000 of the scheme population per day.
The population is usually considered to be
individuals over the age of 15. Although we include
children in the count of individuals and
58 An explanatory note on the Defined Daily Dose system for measuring drug utilisation is on the NHS Scotland
website at http://www.isdscotland.org/isd/3648.html (Accessed 8 May 2008).
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prescriptions, we do not include them in the DDD
calculations for individual drugs as this would
distort the estimate of usage in the adult
population.
We chose the period from 2000 to 2007 in order to
look at trends in usage and prescribing over a
period of time; and to see what effect, if any, the
good practice prescribing guidelines may have
had. We expected to find a pattern of increased
usage up to the time the guidelines were issued
and some reduction over time after that. The data
suggest, however, that the guidelines have had
little or no impact.
The detailed statistical tables are contained in
Appendix 1, but the key findings are presented
here.
Number of Individuals
1. Some 89,721 distinct individuals in counties
Galway, Mayo and Roscommon were
prescribed minor tranquillisers and sedatives
between 2000 and 2007.
2. Almost 80% of these individuals were people
who were entitled to see their doctor and to get
their prescriptions free of charge (GMS), while
the vast majority of the remaining 21% were
people who paid the doctor and pharmacist but
were entitled to claim a refund on the cost of
their prescriptions (DPS). 
3. About 42% were male and 58% female.
General Profile
1. The numbers of people prescribed minor
tranquillisers and sedatives in all three
schemes has increased year on year – up from
slightly less than 25,000 in 2000 to a little over
33,000 in 2007.
2. Looking at averages across the period:
a. Around 54% of those prescribed minor
tranquillisers and sedatives were over the
age of 65. As a general comparator, only
12.5% of the population of the three
counties was aged 65+ in 2006.
b. The percentage of males was 38%, and the
percentage of females 62%. As a general
comparator, the population of the region
was evenly split between males and
females in 2006
c. Some 49% were from Galway, 34% from
Mayo and 17% from Roscommon. As a
general comparator, the population
distribution was 56% in Galway, 30% in
Mayo and 14% in Roscommon in 2006.
d. The average percentages of people in the
GMS and DPS were 52% and 46%
respectively for the period from 2000 to
2007.
3. In summary, women, older people and people
on low incomes are over-represented in the
averages, while men and people on higher
incomes are correspondingly under-
represented.
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Number of Prescriptions
1. The total number of prescriptions written in the
three counties increased every year between
2000 and 2007.
2. People aged 65 or more, who comprise just
12.5% of the population of the region, got close
to two-thirds of all prescriptions.
3. Women, who comprise around half the
population of the region, also got close to two-
thirds of all prescriptions.
4. Some 1.5 million prescriptions – were
reimbursed between 2000 and 2007. Almost
88% of prescriptions went to people with
medical cards, while almost all of the remaining
12% of prescriptions were for people in the
DPS.
a. Across all three schemes, the top five
drugs, measured in descending order of
number of prescriptions, were Temazepam,
Diazepam, Zopiclone, Alprazolam and
Bromazepam. 
i. In the GMS, the top five drugs were
Temazepam, Diazepam, Alprazolam,
Zopiclone and Bromazepam.
ii. Four of the top five in the GMS were also
in the top five of the DPS, albeit in
different rank order, with Bromazepam
displaced from fifth position by
Zolpidem, which joined Zopiclone as the
second and second most popular non-
benzodiazepine hypnotic on the list of
most prescribed minor tranquillisers and
sedatives.
Drug Usage
1. The Benzodiazepine Committee used the
Defined Daily Dose measurement system to
arrive at a rough estimate of the proportion of
the population treated daily with minor
tranquillisers and sedatives. (It gave the
example that a figure of 10 DDDs per 1,000
inhabitants per day would indicate that the
amount used in terms of one normal adult dose
per day would be given to 1% of the population
on average). We followed the same approach
in this study.
2. In the GMS, usage, as measured in Defined
Daily Doses / 1,000 / Day of the scheme
population fell by 2% in 2001, a full year before
the good practice prescribing guidelines for
clinicians were published, but increased every
year except one thereafter: up 15% in 2002, up
7% in 2003, up 7% in 2004, up 4% in 2005,
down 2% in 2006, and finally, up 3% in 2007.
3. In 2000, around 7.5% of the GMS population of
the three counties were using minor
tranquillisers and sedatives. By 2007, this had
increased to slightly less than 10%. In other
words, the good practice guidelines had little or
no effect in the GMS and a pattern of increased
prescribing became more deeply embedded.
4. In the DPS, usage, as measured in Defined
Daily Doses / 1,000 / Day of the scheme
population decreased four years in a row (2001
to 2004) but fluctuated in both directions in the
following three years. The reductions were 7%,
13%, 10% and 1% between 2001 and 2004.
Usage increased by 20% in 2005, fell by 1% in
2006 and rose by 8% in 2007.
5. In 2000, around 1.5% of the DPS population of
the three counties were using minor
tranquillisers and sedatives. By 2007, this
number was largely unchanged, albeit that
some significant reductions were achieved in a
number of the intervening years. From this we
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may conclude that the good practice
guidelines may have had some positive effect,
albeit in a context where usage in the DPS was
small to begin with, and much smaller by
contrast with the GMS.
6. The number of DDDs per 1,000 per day of the
GMS population has been a significant multiple
of the number of DDDs per 1,000 per day of the
DPS population in all years. The multiple was 5
in two years, 7 in four, 8 in one, and 9 in one
year. This suggests that people in the GMS get
from 5 to 9 times the number of DDDs as
people in the DPS. 
7. The quantity of doses per form i.e. the number
of DDDs per prescription form appears to be
well within the good practice guidelines. In the
GMS, the average of DDDs from 2000 to 2007
is 21.54 days supply; while the figure in the
DPS is slightly lower, at 20.08 days.
Long-Term Usage and Prescribing
1. However, in terms of those who are actually
being prescribed minor tranquillisers and
sedatives, as opposed to the numbers who are
estimated to be using them, there are serious
issues with regard to long term usage and long
term prescribing. We defined the former as the
number of individuals in the medical card and
the private schemes who are prescribed > 56
DDDs (two months supply or more) per year for
anywhere from two to eight consecutive years.
We defined long term prescribing as the
number of doctors who prescribe > 56 DDDs
(two months supply or more) per year of the
same drug to the same individual for anywhere
from two to eight consecutive years.
2. This analysis identified that there is a significant
number being prescribed minor tranquillisers
and sedatives for long periods - longer than the
maximum recommended times. Taking the
GMS, DPS and LTI together, a total of 15,935
people, or nearly 18% of all individuals, had
been prescribed minor tranquillisers and
sedatives for two months or more at least once
for up to eight consecutive years. Clearly this
goes far beyond the maximum recommended
period of a one-month, once-off prescription
favoured in the good practice guidelines. GMS
clients i.e. people in the state-funded scheme
account for almost nine out of ten of those
affected; and they outnumber those in the
private, pay-as-you-go scheme by a factor of
between 5 and 18 times.
3. This analysis also identified a significant
number of doctors prescribing to some patients
for protracted periods. The highest number
prescribing two months supply or more at least
once in consecutive years, was for two
consecutive years (389 GPs) and the lowest
number was for eight consecutive years (159
GPs). In all, there were 415 GPs who
prescribed in protracted fashion, as defined, at
least once during the period under study here.
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Concluding Comments
One of the most striking contrasts between the
HRB and HSE data sets for the western counties is
the relatively insignificant numbers of people
presenting for treatment for problem tranquilliser
and sedative use, when compared to the number
who are taking these drugs, often on a long-term
repeat basis.
Moreover, on every significant yardstick – number,
age, gender, daily usage, and long term usage, it
is clear from the prescriptions data that minor
tranquillisers and sedatives are being directed to
those with the least means and the most problems,
to the very people who depend most on the public
health service. 
At one level, the escalating levels of prescribing
may be seen as the only viable response by
prescribers in a context where treatment facilities
are nowhere near adequate to cope with all who
might wish to access treatment to break an
addiction. At another level, however, there is a
deeper question of how long the current situation of
escalating prescribing and inadequate service
provision should be allowed to continue, and what
innovations could be attempted to address the
problems.
These issues are addressed in the next chapter.
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Introduction
In this chapter, we present the views of service
providers who have a role in the treatment of those
misusing minor tranquillisers and sedatives, and
who are in significant contact with these individuals
and their families. We also present the
perspectives of a small number of people who are
recovering from an addiction to these drugs. In that
context, we also took the opportunity to speak with
one person recovering from an addiction to
Codeine, which though beyond the scope of this
study, is a drug known to be widely misused and of
increasing concern to the health authorities.
The intent of this chapter is to document the
experiences of service providers who are dealing
with clients presenting with an addiction to minor
tranquillisers and sedatives, their perceptions of
the root causes of the problem, and their
preferences for treatment and preventive services.
The views and experiences of recovering addicts
complete the picture. In general, qualitative
research is invaluable for tapping knowledge and
experience that is not being documented in
quantitative form.
This chapter begins with a summary of the good
practice prescribing guidelines. These are aimed
at ensuring the proven therapeutic benefits of
minor tranquillisers and sedatives are gained
without their known drawbacks. It continues with an
outline and discussion of a health promotion
perspective on addiction, which offers a suitable
framework for locating where responsibility lies for
the crisis we appear to have with the misuse of
minor tranquillisers and sedatives, and identifying
where responsibility rests for tackling it. The health
promotion model sees individual choice and/or
prescriber practice, at once, as part of the solution
and part of the problem; and the service providers’
best response as being directed to providing a
continuum of care and support, with a strong
emphasis on prevention. The chapter then outlines
the experiences of a number of people who are
recovering from an addiction to minor tranquillisers
and sedatives; and concludes with the
perspectives of a number of healthcare
professionals working in the field of addiction.
Methodology for the Qualitative Research:
The recovery group was comprised of six people
who attended a specially convened Focus Group
at the Hope House Addiction Treatment Centre in
Foxford, Co Mayo. The meeting lasted just over
two hours. Separately, face to face interviews
were carried out with 6 Addiction Counsellors in
HSE West Mental Health, and with 10 Substance
Misuse Counsellors in HSE West Drug Service.
The duration of each of these varied from 45 to 90
minutes and the average was an hour.
Good Practice Prescribing
Guidelines for Clinicians
The Good Practice Prescribing Guidelines for
Clinicians outline the steps which doctors are
expected to take before starting a course of minor
tranquillisers and sedatives, when prescribing
them for the first time, and when managing patients
who are dependent or getting a continuing
prescription.
The first step is to take a full patient history,
including use of alcohol, and licit and illicit drugs.
The next is to inform the patient of the side effects
of minor tranquillisers and sedatives and to offer an
information leaflet. The doctor should then
consider and, if possible, treat any underlying
cause for which these drugs may be prescribed;
consider other services and alternatives; and
consider delaying prescribing until a later visit.
When prescribing for the first time, the guidance is
as follows:
• Start with the lowest recommended dose.
• Prescribe for no longer than four weeks.
• Use phased dispensing where possible.
• Ensure patient-prescriber agreements are
documented.
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• Record all medication prescribed and the
duration of treatment.
• Ensure clear, effective, speedy communication
between prescribers within and between
services.
For dependent patients or patients in receipt 
of a continuing prescription, the doctor is
recommended to act as follows:
• Issue small quantities (a week’s supply at
most).
• Review regularly (usually monthly).
• Use a long-acting benzodiazepine in dosages
no higher than Diazepam 5mg three times daily
or equivalent.
• Use signed consent forms where appropriate.
• Make the patient aware of the long-term risks,
encourage them to withdraw, offer a
detoxification programme at least once a year,
and document all such communications.
• Seek specialist advice before prescribing to
patients who have become dependent through
substance misuse.
Health Promotion Context
Assuming that appropriate use of these drugs
means use to achieve a health and social gain, it
follows that any dilution of the gains from their
continued use for a reason other than the initial
clinical need, or in a dose or to a direction that has
not been prescribed, or for a duration longer than
recommended maximum time, represents
inappropriate use.
In theory, the good practice guidelines should
facilitate the safe and effective use of minor
tranquillisers and sedatives. As Butler (2002)
points out, however, “the practice of using psychoactive
drugs for recreational purposes or as a means of coping
with stress or tedium is ancient and almost universal,
although knowledge of the negative consequences of such
drug use is equally ancient and well-established. Health
policy making in this sphere is enormously complex, since
it has to deal with abstract moral debate about drug use,
popular opinion, economic and other interest group
conflict, and of course research developments in the
biomedical and social sciences.” 59
We noted earlier that a major issue with minor
tranquillisers and sedatives is that they are widely
available and misused, due to poor prescribing by
some doctors and/or decisions by individuals to
take them incorrectly. We will see later that opiate
users often resort to benzodiazepines if they can’t
access opiates, or if they feel the need for a ‘lift’ as
they come ‘down’ from an opiate. Concern is also
growing in the HSE West Drug Service that minor
tranquillisers and sedatives are being used by
younger recreational drug users to ‘manage the
crash’ from stimulants or as a mixer with alcohol.
Those for whom minor tranquillisers and sedatives
are prescribed may have a benign view, or no view
at all, of the downsides of inappropriate use. They
may not be fully aware of the risks, especially
tolerance and dependence. They may not
understand the risks even after being warned.
They may believe the drugs do more good than
harm, even though the benefits no longer occur.
They may have such a trust in their doctors that
they do not question why their prescription is being
continued long after a decision might have been
taken to discontinue it, or why they may be asking
for it to be repeated. 
This research seeks to explain the problem of the
misuse of minor tranquillisers and sedatives in a
health promotion context. It shows that individual
decisions by patients and prescribers have been
instrumental in maintaining a pattern of misuse;
and that public policy and health authorities have
failed to address inappropriate use by controlling
pricing, prescribing and distribution.
59 Butler, S. (2002). Alcohol, Drugs and Health Promotion in Ireland. Dublin: Institute of Public Administration. p vii.
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The evidence also points towards the conclusion
that public policy has failed to reorient health
services for treating benzodiazepine addiction, by
putting the focus on prevention and delivering a
continuum of care that includes medical
intervention (where necessary) and ongoing
supports that help the individual to acquire or
develop personal skills to cope with a life crisis, for
which minor tranquillisers and sedatives might
otherwise be taken.
Ashton (2002) identifies three categories of
alternative techniques:
• Psychological, which consists of behavioural
therapy that aims to replace anxiety-related
behaviours with better adapted behaviours;
and cognitive-behavioural therapy, which
teaches individuals to understand their thinking
patterns so they can react differently to anxiety-
provoking situations.
• Complementary Medicine, which includes
acupuncture, aromatherapy, massage,
reflexology and homeopathy.
• The final category includes exercise and
various other techniques including sports, yoga
and meditation.
The psychological techniques have been formally
tested and give the best long-term results; the
effects of the complementary techniques tend to
be short-lived; and some people respond well to
the other techniques. 60
Adverse Effects of Minor
Tranquillisers and Sedatives
Before recounting the stories of recovering addicts,
it is useful to restate the key points that have been
documented with regard to benzodiazepine
addiction in the UK. These echo the experiences of
most people in our Focus Group, and provide
support for the view that minor tranquilliser and
sedative misuse is best seen in a health promotion
context.
Addressing a House of Commons Health
Committee in 1999, one expert summarised the
issues that led her to conclude that minor
tranquillisers and sedatives “contribute a considerable
unsolved health problem”:
• They have the potential to cause dependence
when taken for longer than four weeks, even in
prescribed therapeutic doses.
• Significant numbers of people suffer withdrawal
symptoms when trying to stop after taking
excessive doses for many years.
• The incidence of protracted withdrawal
symptoms is high.
• There is a continuing high number of long-term
prescribed users despite expert advice that
prescriptions for these drugs should be limited
for two to four weeks.
• There is a lack of knowledge among doctors
generally about withdrawal symptoms and
withdrawal methods.
• There is a scarcity of patient advice and of
support centres.
• There is evidence of a growing problem of
minor tranquillisers and sedatives misuse
among polydrug users.
Recovering Addicts’ Perspectives
A Focus Group was held with six recovering
addicts at the Hope House Addiction Treatment
Centre in Foxford, Co Mayo, to hear their
experiences. Hope House is one organisation
dedicated to helping people recover from
alcoholism and other addictions. Its services
60 Ashton, H. (2002). Benzodiazepines: How they work and how to withdraw.
http://www.benzo.org.uk/manual/bzcha03.htm (Accessed 25 September 2008).
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include residential and continuing care for adults,
and support programmes for families. Its
philosophy is to treat alcohol addiction, drug
dependency and compulsive gambling as chronic,
progressive diseases. The focus is on total
abstinence from mood-altering substances and
improved quality of life for all.
The five female participants had all been addicted
to a minor tranquilliser or sedative, which was their
minor drug problem. Alcohol was the major
problem in all cases. The male in the group was
recovering from an addiction to Codeine. Although
this research is concerned with minor tranquillisers
and sedatives, the experience of the male
participant is presented as a separate section at
the end of the report, as his story echoes the
experiences of those who have been addicted to
minor tranquillisers and sedatives, and indeed
echoes the increasing concerns among healthcare
professionals about rising levels of addiction
occasioned by the explosion in sales of over-the-
counter combination products containing Codeine.
The Focus Group session was recorded with a
digital recording advice, which was played back
by the author when writing this chapter. The
recording was done with the knowledge and
approval of the participants. A commitment was
given that the recording would be destroyed when
the research was completed and the final report
published. This has been done.
Anne’s Story
Anne is married and recovering from an addiction
to alcohol and minor tranquillisers. She has used
Diazepam (Valium), Lorazepam (Ativan),
Alprazolam (Xanax), ‘sleeping tablets’, Solpadeine,
and the more potent preparation Solpadol (a
prescription-only painkiller containing 30mg of
Codeine per tablet as opposed to the 8mg of
Codeine in Solpadeine).
She recalls taking up to 50mg of Alprazolam a day,
along with antidepressants and sleeping tablets,
though she says she took care to get separate
prescriptions for the different drugs to avoid
detection.
Anne says she started drinking while at college.
She began getting panic attacks and was given
Valium by injection and a prescription for the tablet
form of the drug on her first visit to the doctor. “And
that’s how it started”, she says. “I swore I’d never be
without it again.”
She continued her prescription after college, taking
it as directed for few years before increasing the
dose to cope with general life issues. Anne admits
she “did the rounds” of surgeries and pharmacies
locally and farther away. Her “terror” was that she
would accidentally go to one where she had
recently been. She kept a diary of the places she
had visited, in order to avoid being caught. “It was
like a crossword puzzle”, she says. “Where would I go?
How many would I need? What would I do if I ran out?
There was always a panic burning in the back of my
head.”
Anne recalls that counselling was never offered
whereas a prescription always was, though she
admits she would have “lied through [her] teeth” to
get a prescription because she “had to have them. It
was that or die.” Living and working in a small
community, she consulted the same doctors many
times, but believes her status was the reason she
was never questioned about her continued
requests for a prescription.
Anne cannot recall any instance where she was
advised by a doctor that minor tranquillisers and
sedatives are addictive and should only be taken
for short periods: “nobody ever said that to me.” She
found that if a prescription was written up once,
there was never any problem in getting it repeated,
though she did encounter a particular difficulty on
one occasion in one town because the dispensing
pharmacist was convinced that the dose and
directions had been entered incorrectly on the
prescription form.
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She realised “the game was up” when doctors finally
became reluctant or refused to give her a
prescription; and her family witnessed her health
and appearance diminish as a result of her
addiction.
Anne was quite upfront in pointing out that she did
not attach any blame to any doctor who had
prescribed minor tranquillisers and sedatives for
her. This was her addiction and she herself was
responsible for letting it continue for so long.
However, she questions whether healthcare
professionals have enough training to recognise
and respond to the signs of addiction.
That prompted a general discussion in the group.
In summary, the consensus was that a doctor may
be aware a patient is addicted to minor
tranquillisers and sedatives but continues to
prescribe anyway, because they have doubts
about the patient’s ability to cope without the
drugs, or doubts about their own ability to wean the
patient off them, or because they may not know
enough about or even believe in alternative
therapies themselves.
Mary’s Story
Mary is married and recovering from an addiction
to alcohol and minor tranquillisers. Mostly she has
used Temazepam (Euhypnos, Nortem, Normison)
but she has been prescribed Alprazolam (Xanax).
She discovered Temazepam when she took one
from a relatives’ prescription in the belief it would
cure a hangover she had – “and it gave me such a
high”, she says, “that I thought this was the answer for
me. I used to suck out the liquid stuff and leave the shell
for him.”
Mary was caring for another relative at the time and
requested the doctor to include Temazepam on the
prescription. This became her supply. However,
she soon felt compelled to find another way of
getting them as the doctor advised this other
relative to stop taking them.
Mary worked in an environment where she was
able to access minor tranquillisers and sedatives
with relative ease. She became so preoccupied
with Temazepam that she would have developed a
“headache” by the time she got to work; and that
provided the pretext go unsupervised for a couple
of Paracetamol. “That went on and on for a few years
and I could not survive a day without fistfuls – and I
mean fistfuls.” Mary says she would take four or five
Temazepam at a time having stolen up to 15, but
after “a few hours” needed more. She even resorted
to licking the tissues in which she hid the drugs so
as to get every last trace.
Mary later obtained a prescription for Alprazolam.
However, she continued taking Temazepam illicitly
and even resorted to photocopying her
prescriptions. She says she continued with this
lifestyle for as long as she could but eventually, she
collapsed and was admitted to hospital.
She believes she used her relatives’ prescriptions
for up to three years. Then she got her own
prescription but continued to top up in the usual
way.
Mary recalls that she felt the drink wasn’t working
whereas the tablets were and that when she came
to Hope House, she thought it would be possible
for her to continue taking minor tranquillisers while
being treated for alcohol addiction. She says she
had “no understanding of tablets” but felt that they
were “blotting out pain and problems… stuff I wasn’t
talking about or dealing with. Life revolved around
tablets. I’d go through iron to get them. I’d lie, steal,
anything.” She acknowledges that alternative
supports were never offered, but accepts also that
she wasn’t interested in hearing about them. In her
mind the problem was at home or somewhere else.
This prompted a general discussion in the group
about ingenuity of addicts in getting a minor
tranquilliser or sedative prescribed and repeated.
There was a consensus that a true picture of the
nature and extent of a person’s addiction is rarely
given at first assessment, and that this underlines
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the need for healthcare professionals to be aware
of and alert to “the whole picture of addiction”. There
was also a consensus that alcohol is often the
primary addiction and that while certain minor
tranquillisers are valuable for detoxification, the
fact that clients may find them so beneficial means
a potential new addiction may develop in some
cases.
One participant described GPs as the “custodians”
of good prescribing, but felt that there is “no
consequence against them for doing the wrong thing.
None.” Others felt GPs need to make themselves
aware, and need to press patients to be honest
with them (e.g., about a possible addiction to
alcohol), and that they should look critically at such
issues before prescribing.
Della’s Story
Della’s primary addiction is to alcohol and she was
given a prescription for Alprazolam (Xanax) while
hospitalised. However, she only used it for about
six months, as she believed alcohol was the “cure”
for her panic attacks. She recalls that she got
“terrible blackouts” and went “off [her] head” if she
mixed alcohol with her prescription.
When Della was using Alprazolam, she felt she had
to take it just to ward off the panic attacks she knew
she would have from being deprived of alcohol.
However, she felt they only increased her anxiety,
and gives this as the reason why she did not take
them for longer.
She says she had no idea at the time what she was
getting “the little white tablet” for. She used three to
four a day under medical supervision and felt they
were “easily got” because the doctor knew she was
trying to stay off alcohol. She says the GP never
spoke to her about their addictive potential or the
desirability of using them for a short 
time only.
Della feels Alprazolam got her “through the gaps”
while she was abstaining from alcohol, but says
she had no knowledge or awareness at the time
how addictive it could become: “no-one told me”.
She believes that awareness of the issues has
improved among doctors since she went into
recovery, but feels she could “wrangle them” if she
wanted.
Kay’s Story
Kay is married and recovering from an addiction to
alcohol and the non-benzodiazepine hypnotic,
Zopiclone. She  also worked in an environment
where she could access them easily. Kay was quite
frank in admitting that she made a deliberate,
conscious decision to take Zopiclone – “I had no
real problems in my life, only a pain, nothing that
wouldn’t have gone away” – though she says she was
unaware at the time of the long-term effects.
Although Zopiclone was her preferred choice, she
would take a benzodiazepine if that were not
available. She believes she was dependent soon
after her first dose. It gave her a very relaxed
feeling that “things are going to be alright and that’s
exactly how I felt. For the next four years, I probably slept
my life away. That’s all I wanted to do, go to bed, turn off
the lights, pull the curtains and don’t wake me ‘til another
tablet is due.”
Kay recalls that her first prescription was written for
three months but she used it up before then and
had no trouble getting a repeat prescription or
accessing a supply in other ways.
She describes how addiction took over her life: “I
nearly lived to go to work to get the tablets”, she says.“It
was relentless. They never left my head from morning
until night. It was total torture really.” In the end, she
didn’t even count her dose, but recalls that five
tablets “would not even have knocked me out. If I woke
up in the middle of the night and thought there was a
remote chance I wouldn’t go back to sleep, I’d take another
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one. In the middle of the day, when the kids were at school
– oh I’d get all my housework done, my jobs done, so
everything would look like it was under control, I’d have
the dinner cooked – I’d take a tablet, pull the curtains, get
into bed and set the alarm clock ‘til it was time to pick
them up from school. It was the purpose of every minute of
every day.”
The tipping point was “a mental meltdown”. She told
her husband she was “drinking too much and taking a
ball of tablets … I didn’t know how I’d live without them
but they’d stopped working anyhow.That’s why I ended up
having to go back to mix the alcohol with them … I should
have been dead – the amount I was taking.”
Kay admits that her GP did offer a specialist
referral but she herself “wasn’t willing to listen. It’s not
that it wasn’t said. I just didn’t give them room to expand
on it.” The GP made her aware of Hope House and
she opted to do ‘cold turkey’ rather than tapering
down. “I thought I was going to die”, she says. “I had
pains in my chest. I had pains in my head. I couldn’t even
go into the shower. It was desperate. I didn’t eat for two
weeks. It was awful. I couldn’t even describe it. Lying in
bed and trembling and shaking, not knowing was there
ever going to be an end to it.”
She feels there are means other than minor
tranquillisers and sedatives for solving problems
and she expressed the view, which was strongly
supported by others, that there should be facilities
to “detox with dignity”.
Eileen’s Story
Eileen is married and recovering from an addiction
to alcohol and minor tranquillisers. She has a
history of panic attacks and though she didn’t want
to drink, she did so because she got “frightened”.
Her GP initially prescribed Bromazepam (Lexotan)
for a very short period and advised her to come for
a further consultation when the prescription was
used up. “That was my route into tablets”, she says.
She took the drug “on and off” for a year and could
use a month’s supply in two weeks.
Eileen describes herself as a “binge drinker”, but
even before she was prescribed minor
tranquillisers, she had “discovered” a cough linctus
containing Codeine. When she wasn’t drinking at
that stage, she was taking the cough bottle
instead. She says she didn’t know anything about
Codeine at the time; only that she needed the
Benylin with the “blue stripe”.
During a detoxification, she was prescribed the
benzodiazepine Chlordiazepoxide, a treatment for
alleviating alcohol withdrawal symptoms. Her
greatest concern then was whether she would be
getting a prescription for it when she went home.
Eileen was prescribed Alprazolam on discharge. A
three-month supply could be used in a month. She
would get a repeat by “lying; saying I lost my
prescription; going to different doctors.” She found that
Alprazolam tended to suppress the anger that
normally accompanied heavy drinking. Eileen was
taking alcohol and minor tranquillisers together
before she came to Hope House. 
She says no alternatives were offered to her at any
time. She believes there needs to be a mix of
responses to address the issues of individuals
taking addictive prescription drugs inappropriately,
of doctors prescribing them for longer than may be
necessary, and of the public in general not being
prepared to work harder at sorting out their
problems without resorting to drugs. She worries
that people put their faith and trust in doctors to do
what’s right without knowing enough about
addictive prescription drugs themselves, which
may in turn lead to an accidental addiction.
However, she also acknowledges that people have
a personal responsibility to become more informed
and educated.
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One of the main aims of this research has been to
explore the experiences of service providers who
are dealing with clients with a benzodiazepine
addiction, to discuss their perceptions of the root
causes, and to document their views on how
services could respond.
There are two main groups in the Health Service
Executive dealing with addiction. The first is the
Community Substance Misuse Counsellors in the
HSE Drug Service. We carried out face-to-face
interviews with ten of these personnel. The second
group includes the Addiction Counsellors in the
HSE Mental Health Service. We carried out face-to-
face interviews with six of them. The author wrote
up a detailed note of each interview and this was
passed to each person to ensure it was factually
accurate and reflected the views expressed. These
amended notes provided a basis for the discussion
that follows.
Readers may wish to note that the Addiction
Service in HSE Mental Health is geared to adults
over 18 who are addicted to alcohol and/or
prescription drugs. The HSE Drug Service, on the
other hand, is for people under 18 with alcohol
addiction, and for people over 18 with drug
addiction. Referrals to Mental Health are arranged
through a GP. The Drug Service is a self-referring,
direct access facility.
A patient or client presenting to either service may
be known or suspected to have an addiction to
minor tranquillisers and sedatives, but this is no
guarantee they will get the same range of services.
In short, there is no over-arching obligation on
service providers in the two care settings to work
together in anything other than a goodwill fashion
to deliver a tailored package of care and support,
which meets the needs of an individual. This is not
to say that co-operation does not occur; only that
co-operation across sectors can be patchy,
fragmented and unstructured.
In practical terms, the effect is that a person who
presents with an alcohol and/or a benzodiazepine
addiction to a GP will be referred to Mental Health,
where they are likely to have ready access to
specialist supports and multidisciplinary care.
However, a person with an opiate and/or
benzodiazepine addiction who comes to the Drug
Service is unlikely to get detoxification, or an
assessment by a Consultant Psychiatrist, or
access to the full range of services provided by a
multidisciplinary team.
None of this is equitable, or in keeping with the
vision of the national health strategy, Quality &
Fairness, which gives an explicit commitment to a
health service that “supports and empowers you, your
family and community to achieve your full health
potential … is there when you need it, is fair, and you can
trust … and encourages you to have your say, listens to
you, and ensures your views are taken into account.”
During our interviews with various service
providers, we found a commonality of concerns
expressed. Concerns were repeatedly expressed
about inappropriate prescribing by some doctors;
about the failure of public and regulatory
authorities to exercise greater controls over
inappropriate prescribing and dispensing 
(e.g., through changing the drug scheduling 
and reimbursement regimes); and about the
consequences of lax controls as drivers of the
black market.
Service Providers’ Perspectives
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Grouping the views of the various Addiction
Counsellors we interviewed into over-arching
themes, the following views emerged on the root
causes of misuse and the appropriate treatment
and service response:
a) Inappropriate Prescribing
b) Individual Choice in Misuse
c) Public Policy & Remuneration Issues
d) Diversion and Leakage
e) Key Service Issues
a) Inappropriate Prescribing
The Addiction Counsellors interviewed readily
acknowledged the proven therapeutic benefits of
minor tranquillisers and some noted that doctors
are increasingly aware of their addictive potential,
and so are more inclined to prescribe for a limited
period and then review the prescription.
One identified this apparent trend as a key reason
why the Addiction Service may now be seeing
fewer people with a benzodiazepine addiction than
in earlier decades where inappropriate prescribing
was in their view, more commonplace. Others felt,
however, that GPs would more likely try tapering a
prescription than referring a patient to the
Addiction Service. Were this true, it would suggest
that only those with the most problematic
addictions would likely be referred for specialist
treatment. One noted that it’s only when an
addiction to minor tranquillisers and sedatives
becomes really problematic that the mental health
and primary care settings tend to engage, but even
then it’s more a case of crisis management than
proactive care.
Several Addiction Counsellors expressed the view
that this addiction is a significant hidden problem
for society. Two remarked that it often goes hand-
in-hand with alcohol addiction (the reason for the
great majority of referrals to the Addiction Service);
and that it may be created or conditioned by
inappropriate prescribing of minor tranquillisers
and sedatives in the mental health services or in
general practice in order to assist in abstinence. 
Some GPs are said to experience pressure from
some patients to prescribe inappropriately; a
difficulty claimed to be compounded if the waiting
room is crowded. In this situation, the responsible
prescriber may be faced with a choice between
refusing the patient’s request, or writing a
prescription and perhaps starting or stoking an
addiction.
A general concern was expressed that many
individuals have built up a tolerance and
dependence as a result of being maintained on
minor tranquillisers and sedatives long after the
optimal therapeutic period. As one Addiction
Counsellor put it: “I have young lads that would have
been on the buildings in England and when they came
back they were on 40mg of Valium four times a day. We
got them down to 30mg a day and we had wrecks. We’ve
had men turned into babies; that’s what it looked like.”
Discussions have taken place in primary care (and
separately in some mental health services) in the
three western counties about the need to ensure
appropriate prescribing at all times. These have
proved fruitless. A number of individuals working in
the different settings have expressed the view that
inappropriate prescribing is not an issue that
concerns the medical profession greatly; or the
health authorities, which appear not to demand
more rigorous control and accountability for
prescribing.
One Addiction Counsellor noted the need for an
effort to shift public attitudes around prescribing,
arguing that an unequal power/prestige
relationship between prescriber and patient, and a
lack of awareness and understanding of the
benefits and risks of prescribed drugs on the part
of the patient, means they leave much to the
prescriber’s discretion.
Views of Addiction Counsellors
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b) Individual Choice in Misuse
A second theme to emerge in the interviews with
Addiction Counsellors concerns the choices that
individuals make (or feel forced to make because of
their addiction) about the use and misuse of minor
tranquillisers and sedatives, albeit where they may
not fully understand their addictive potential or the
consequences of taking them incorrectly.
One Addiction Counsellor remarked, for example,
that several individuals in the one household may be
getting minor tranquillisers prescribed by their GP
and by the Mental Health Services, yet share each
other’s prescriptions in the home. In cases of alcohol
and minor tranquilliser co-dependency, the initial
focus of the treatment will be on the primary
presenting problem, which invariably is alcohol.
When attention turns to the secondary addiction, the
client may be reluctant to come off the minor
tranquilliser, as in mental terms, they have sought
treatment for an alcohol not a prescription drug
addiction, and because they see no harm in
continuing a drug that was prescribed by a doctor in
the first place. This ties back to the experience of one
member of the Users’ Focus Group, who said she
knew nothing about “white tablets” but hoped she
could continue them while in treatment for alcohol
addiction.
Others emphasised that one of the biggest problems
an Addiction Counsellor or GP faces when dealing
with a person in the early stages, is their reluctance
to be honest, especially if they are looking for a minor
tranquilliser to alleviate anxiety, which itself may be a
symptom of substance misuse or dual diagnosis
(misuse problem and mental health issue together).
One Addiction Counsellor cited the example of a
client who had been treated for alcohol addiction
and did not disclose at the time that he was also
using minor tranquillisers, but at a later presentation
to the Psychiatric Services was found to be taking
70-80mg of Diazepam a day, which he was buying
on the street. The problem of establishing what a
client is taking is compounded by the weakness of
the testing for minor tranquillisers. This can detect
their presence, but reportedly, not their
concentrations.
c) Public Policy & Remuneration Issues
A third theme to emerge from the interviews with
Addiction Counsellors concerned the usefulness of
existing policy and controls for ensuring
appropriate prescribing, minimising leakage to the
street, and disentangling ‘perverse’ financial
incentives which tend to reinforce inappropriate
prescribing and dispensing. A number felt the
existing situation was unsatisfactory.
One Addiction Counsellor advocated a twin-track
approach to tackling misuse and leakage. The first
would involve elevating the control schedule so
that prescribing and dispensing become much
more closely monitored and regulated, as is the
case with drugs like Morphine, Pethidine and
Dihydrocodeine. The second would involve
introducing a penalty for inappropriate prescribing
and dispensing in place of the current reward of an
automatic fee for prescriber and dispenser, which
as we have seen, has now begun to exceed the
ingredient costs of minor tranquillisers and
sedatives reimbursed under the two largest drug
refund schemes.
A second Addiction Counsellor argued for a
flexible protocol governing prescribing, which
would reflect the requirement for greater control on
the one hand, and the reality of the current position
for patients and in society on the other. Among the
issues to be considered would be:
• The requirement for a tapering regime to give
the patient or client the confidence that they
can quit in a reasonable time.
• The possibility that patients or clients will top up
on the street if their prescription is restricted in
a way that fails to take account of their needs
(e.g., for tapering and alternatives).
• The reality that minor tranquillisers are easily
accessible on the street and likely to remain so
no matter what the controls.
A third Addiction Counsellor supported the idea of
a protocol, not just to minimise inappropriate
prescribing, but also to drive structured
collaboration between primary care and mental 
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health, so that prescribing takes place in the
context of key personal development strategies,
such as behavioural or cognitive-behavioural
therapies, and as part of a continuum of care.
d) Diversion & Leakage
Several Addiction Counsellors expressed concern
that the current controls are so lax they are driving
a thriving black market for minor tranquillisers.
According to one, Diazepam can be bought on the
street for as little as €0.50 a tablet in some places.
We have already cited at least one case of an
individual who was found to be illicitly misusing
some 70-80mg of Diazepam a day.
In many instances, the Addiction Counsellors (and
the Substance Misuse Counsellors) mentioned
Diazepam, Temazepam and Alprazolam as among
the drugs most often encountered in prescribed or
illicit use.
Diazepam is among the most commonly
prescribed benzodiazepines nationally on the
community drug reinbursement schemes. The fact
that the other two are also among the most
commonly prescribed suggests that there is
significant leakage from legitimate prescriptions to
the street.
We have also noted the concerns expressed by
some about a situation where the public purse
funds some or all of the drug costs, and in some
schemes all of the prescribing and dispensing
fees, but where no public authority appears to
attach any real interest or urgency to reducing
inappropriate prescribing and containing
potentially avoidable costs.
The potential for leakage is compounded where
there is irregular or no review of a prescription in
the context of a broader assessment of whether the
issue for which they were prescribed has been
resolved. If this is not done, the patient may end up
with a long-term repeat prescription and, if so
inclined, can opt to sell all or part of it on the 
black market.
e) Key Service Issues
The most critical of these are the lack of a full data
collection and information-sharing capability
(which would aggregate data held by the HSE and
NDTRS); and the lack of structured,
multidisciplinary working between primary care,
mental health and the drug service in delivering a
total care package for all clients, including those
with dual diagnosis.
The current problems are evident in several
respects. We have previously noted the experience
of one of the Addiction Counsellors, who has cited
examples where minor tranquillisers are being
prescribed, without cross checking, in different
settings for individuals in the same household, and
of the people themselves then sharing them
at home.
Moreover, when minor tranquillisers are used as a
first-line treatment, without apparent due prior
thought for the alternatives, the opportunity to
empower the individual to try and manage their
condition through self-reliance and complementary
supports rather than drugs may be forgone.
Many of the Addiction Counsellors spoke about the
need for and the value of a joined-up service
embracing a wider, deeper, structured co-
operation between primary care and mental health
services, for tackling the root causes of misuse.
The objective would be to control prescribing of
minor tranquillisers and sedatives through
structured co-operation and information sharing
between settings, and seamless access to a
continuum of care.
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The views expressed by the Substance Misuse
Counsellors on the root causes of misuse and the
appropriate treatment and service response are
very similar to those put forward by the Addiction
Counsellors.
Again, it’s worth remembering that the focus and
client base of the respective services is somewhat
different and that the effect of having two different
approaches – medical vs. harm reduction – means
it is difficult for the chaotic drug user to access
psychiatric assessment and inpatient
detoxification, which are likely to be readily
accessible where an individual accesses the HSE
West Mental Health Service via a GP.
From our discussions with the Substance Misuse
Counsellors, a general profile of those who access
the Drug Service and have a benzodiazepine
addiction would be as follows: lower socio-
economic groups; largely dependent on social
welfare; low educational attainment; not in
employment; and in some areas, a noticeable
number of males and females from the Traveller
Community. One Substance Misuse Counsellor
cited the example of a training group for Travellers
where all the female participants had been taking
minor tranquillisers on a long-term, prescribed
basis, not necessarily for depression arising from
within, but for dampening feelings of anxiety and
low mood related to their socio-economic situation.
Grouping the views of the various Substance
Misuse Counsellors we interviewed into over-
arching themes, the following emerged on the root
causes of misuse and the appropriate treatment
and service response:
a) Inappropriate Prescribing
b) Individual Choices in Misuse
c) Diversion and Leakage
d) Key Service Issues
a) Inappropriate Prescribing
The Substance Misuse Counsellors acknowledged
the therapeutic benefits of minor tranquillisers and
sedatives and noted that doctors generally are
increasingly aware of their addictive potential, so
are more inclined to limit their prescriptions and to
review them more frequently.
One Substance Misuse Counsellor says, however,
there is a “serious” prescribing issue, which is not
reflected in the numbers presenting to the Drug
Service. In other words there is likely to be a
significant hidden problem.
This Substance Misuse Counsellor and a number
of colleagues believe the roots of misuse are to be
found in the sheer availability and normalisation of
minor tranquillisers from prescribed and illicit use.
First, they say long-term prescribed use causes
dependence and discourages the individual from
quitting. Second, they argue that widespread, illicit
use stems, not just from the ease of disappearing a
significant number of the vast quantity of minor
tranquillisers authorised on legitimate
prescriptions, but also from a mistaken mindset
that appears to regard them as benign because
they are prescribed and dispensed by expert,
respectable, regulated healthcare professionals.
Another criticised the “blasé attitude to Diazepam”
among some prescribers, and expressed concern
that doctors appear not to be held accountable for
prescribing decisions that are actually driving a
vibrant street trade. Others expressed the view that
the status of GPs and Pharmacists as independent
contractors means they have little incentive or
obligation to engage with the authorities to tackle
the problem.
Some GPs do seek advice from the Drug Service
before writing a prescription for a minor
tranquilliser, where they have become aware the
patient has an opiate addiction. Some will also
refer a patient who has “hit a brick wall” in tapering
Views of Substance Misuse Counsellors
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down, but in general there is little structured
contact between GPs and the Drug Service; and
nothing of the kind underpinning the Methadone
Programme, where there has to be a named GP
sharing the care and communicating proactively
on medicines  they prescribe.
We were informed that relatively few GPs are
interested in being very closely involved in
improving the health and well-being of the most
marginalised groups and that most are likely to
simply write a prescription, which is only partially
used before being added to a bag or box of
medications. With regard to some marginalised
groups, such as homeless people, there appears
to be a strong culture of individuals ‘prescribing’ for
one another, which has obvious implications in
terms of the amounts circulating among groups
and in the black market.
b) Individual Choices in Misuse
Clients of the Drug Service who are misusing minor
tranquillisers are likely have taken one of two routes
there. Some will have begun by experimenting with
a relatives’ prescription, then got their own when
tolerance and dependence developed, and then
started topping up on the street when this was
used up. Others would include them in a polydrug
cocktail and would obtain all of what they need on
the street.
One Substance Misuse Counsellor divided minor
tranquilliser users into:
• ‘Dabblers’: mid to late-teens who take them
after bingeing on stimulants, or as a mixer with
alcohol;
• Polydrug users: adults in their mid-20s to mid-
30s who have normalised them into a cocktail
of drugs;
• Prescribed users: who got them for a life crisis
but never resolved the crisis and maintained
the prescription; and
• Dual diagnosis – an underlying mental health
disorder combined with a substance addiction.
All of the Substance Misuse Counsellors reported
that clients on heroin use benzodiazepines as an
adjunct or a substitute; and that users of stimulants
such as cocaine and ecstasy also use them to
“manage the crash”, as one put it. Clients will often
have been taking them for several years before
they present with another drug addiction; and it is
rare for any client to think about their use of minor
tranquillisers as a problem, which makes a difficult
addiction even more difficult to manage.
Some clients will have a “small script”, which they
may top up as required on the street, typically with
Diazepam; and an exceptional client has made
what one of the Substance Misuse Counsellors
regards as a credible claim to be taking 60-70mg
Valium in a single weekend.
A number of the Substance Misuse Counsellors
who are working with clients aged from mid-teens
to mid-20s have flagged some significant changes
in the drug scene. It was noted, for example, that
minor tranquillisers are commonly used after a
binge of stimulants. Some Substance Misuse
Counsellors are now reporting minor tranquillisers
being used as a starter drug where previously
solvents were used; and that young adolescent
males are mixing them with alcohol.
c) Diversion and Leakage
Several Substance Misuse Counsellors worried
about the availability of large quantities of street
Diazepam, with some remarking that a client is less
likely to misuse a prescription for a tranquilliser
other than Diazepam for fear of being cut off by the
GP, but will top up with Diazepam bought on the
street.
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As mentioned previously, a number of the
Substance Misuse Counsellors believe the roots of
misuse are to be found in the sheer availability and
normalisation of minor tranquillisers in both
prescribed and illicit use. In other words, high rates
of prescribing ensure a ready supply for a vibrant
black market, which could be tackled with simple,
practical measures, such as limited prescribing
and phased dispensing.
d) Key Service Issues
Four of the Substance Misuse Counsellors felt that
one good way of tackling misuse of minor
tranquillisers and sedatives would be to provide a
better education for patients, professionals and the
public about their:
• Addictive nature
• Limited therapeutic value
• Potential to cause harm even though they may
appear harmless because they are prescribed
and dispensed by experts.
All of the Substance Misuse Counsellors were
united in their desire to see an integrated treatment
and service model – comprised of the Drug
Service, Mental Health Service and Primary Care –
accommodating the medical and harm reduction
models, and delivering a comprehensive,
accessible, individualised continuum of care and
supports to all clients, including those with dual
diagnosis, irrespective of the setting in which they
present.
They also highlighted two further current gaps; lack
of access to detoxification for the chaotic drug user
and the need for a so-called ‘Tranqs Clinic’, which
is not overtly identified with the ‘Drug Service’, so
as to encourage benzodiazepine users to come
forward for help.
Concluding Comments
The aim of this chapter has been to explore the
misuse of minor tranquillisers in a health promotion
context with recovering addicts and key healthcare
personnel working in the field of addiction.
We have demonstrated that individual decisions by
patients and prescribers have been instrumental in
maintaining widespread misuse; and that public
policy and authorities have failed to address
inappropriate use by controlling three key drivers:
pricing, prescribing and distribution.
The evidence also points towards a conclusion that
public policy has failed to reorient health services
for treating addiction to minor tranquillisers and
sedatives, by putting the focus on prevention and
delivering a continuum of care that includes
medical intervention (where necessary) and
ongoing supports that help the individual to learn
new skills to cope with a life crisis, for which minor
tranquillisers and sedatives might otherwise be
prescribed.
Regarding the experiences of the recovering
addicts, each was frank in admitting that they had
made significant personal choices, and in
emphasising that they did not blame others for their
addiction. However, it appears none was aware, or
made fully aware, of the risks of tolerance and
dependence when they were prescribed minor
tranquillisers; and none seemed able or willing to
recognise and act early on the warning signs.
All of the evidence suggests that it was easy to get
a prescription and easy to get it repeated, which
suggests that inappropriate prescribing was at
least as important as personal choice in feeding
addiction.
That said, in two cases, individuals were able to
access the drugs at work, which meant they were
able to by-pass their GP. In this situation, no
presciber could have exercised effective control,
though it does raise questions as to the
effectiveness of the management and professional
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controls on the movement of prescribed drugs in
certain healthcare settings.
Some participants also appeared to have a benign
view of the risks of misuse, believing that their
alcohol addiction was more problematic and
hoping that they could continue with minor
tranquillisers while abstaining from alcohol. Most
went to great lengths to conceal their addictions
and to avoid confronting them until it became
absolutely necessary.
None appears to have been offered an alternative
or complementary therapy by default treatment,
though some admitted they weren’t interested even
if it was. This tends to confirm that alternative
services were not generally considered by
practitioners, patients or service providers as a
viable alternative; and to underline the point that a
person will not confront an addiction until they
personally feel ready to do so.
We have seen that the Addiction Counsellors in
Mental Health and the Substance Misuse
Counsellors in the Drug Service are both
concerned about the same broad issues, and that
these also fit neatly to the health promotion
perspective on addiction. These issues include:
• Continuing inappropriate prescribing by some
doctors.
• Personal choices by some individuals to use
minor tranquillisers and sedatives
inappropriately, often in polydrug mix.
• The failure of the public health authorities and
professional regulatory bodies to take
concerted action.
• The continuance of a reimbursement regime in
the community drug refund schemes where
professional fees are paid automatically
regardless of whether prescribing of dispening
is appropriate or inappropriate.
• The ease with which significant quantities of
minor tranquillisers and sedatives, especially
Diazepam, can ‘disappear’ due to a lack of
control on prescribing and distribution.
The interviews with service providers have also
helped to highlight real, but repairable,
weaknesses in the current service models,
particularly the practical impact of using two
different care models: the abstinence approach
favoured by the Mental Health Service and some
not-for-profit providers; and the harm reduction
perspective underpinning the Drug Service.
Ideally, the two should be accommodated to reflect
the reality of the drug problem, which is that, while
abstinence is always preferable, it is not always
achievable. That said, our interviews suggest an
increasing recognition of the value of a joined up
care and service model.
The creation of a single, unitary Health Service
Executive provides an opportunity for all
concerned to re-examine their assumptions and
approaches, and to move towards a common
model, which ensures that everyone has the same
right and opportunity to access the same
continuum of high-quality interventions and
complementary supports, with a package tailored
to their individual needs.
This chapter complements the analysis of data
from the previous chapter, with a broader
discussion based on the expertise and experience
of people who work in the field of addiction, and
the insights of those who have experienced it. This
has been a valuable exercise and there is much for
healthcare professionals and decision makers to
consider.
A number of wider issues emerged. Chief among
these is the question of data availability and data
collection. The primary data source about those
presenting for treatment for addiction to minor
tranquillisers and sedatives is compiled by the
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Health Research Board from periodic statistical
returns from the Community Substance Misuse
Counsellors and others, and latterly the Addiction
Counsellors in Mental Health. The most significant
issue here – and this is confirmed in the personal
interviews – relates to the miniscule proportion of
individuals presenting for treatment compared to
the number who may need help to beat their
addiction and encouragement to come forward.
The inclusion of the Addiction Counsellors will
ensure that a more complete picture of those
presenting for treatment can be compiled. The
major gap is that General Practitioners, who may
be the first to spot the signs of a potential
addiction, are not actually part of the group making
statistical returns. This is a major gap, which ought
to be closed.
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There are three parties to every
prescription - the prescriber, the
pharmacist and the patient.
43
Summary and
Recommendations4
44
Summary
This study confirms that prescribing minor
tranquillisers and sedatives is excessive and
routine in the western region. We identify a range of
actions, including more rigorous regulation, more
rational prescribing, tighter controls on distribution,
further education and training for doctors and
pharmacists, better information for patients, and an
over-arching requirement for equitable access to a
continuum of medical and non-medical supports
as measures that could be considered for
maximising benefits and minimising drawbacks.
1. Minor tranquillisers and sedatives are
psychoactive drugs with proven clinical and
quality of life benefits for the individual, so long
as they are used correctly for no longer than
four weeks.
2. Although there is compelling evidence of
serious health risks from incorrect usage,
including tolerance and dependence, minor
tranquillisers and sedatives continue to be
prescribed, used and misused extensively.
3. In Ireland spending on minor tranquillisers and
sedatives by the public health service under
the main community drug refund schemes has
doubled in eight years and the total spend from
2000-2007 is €168.9 million.
4. The Department of Health and Children issued
good practice prescribing guidelines 
for clinicians in 2002 to encourage more
rational use and prescribing, but these appear
to have had little impact on prescribing
practices, especially for women, older people
and people in a deprived socio-economic
situation.
5. The HRB figures illustrate the profile of those
accessing the Drug Service. However, for most
of these clients, minor tranquillisers and
sedatives are a secondary rather than a
primary drug problem. In addition, because the
Mental Health Service has just started reporting
to the National Drug Treatment Reporting
System, it will be some time before there is a full
picture of those coming for treatment. That
said, these data support four interm
conclusions:
a. Very few people are coming forward for
treatment when compared to the numbers
receiving prescriptions.
b. Males make up the majority of cases
presenting, even though females get most
of the prescriptions.
c. Most of those presenting are under 40
whereas the majority of prescriptions go to
people over 40.
d. The pre-eminence of Diazepam on the
‘street’ is likely due to the fact that it is
prescribed very frequently and often in
large quantities, making it easy to divert.
6. The HSE data provide’s compelling evidence of
the extent to which prescribing has escalated;
and the numbers who may be addicted from
inappropriate long term use stand in stark
contrast with the numbers presenting for
treatment for problem drug use.
7. The health promotion perspective on addiction
explains that individual choices and decisions
on the part of patients, prescribers,
pharmacists and the public health authorities
have been instrumental in maintaining a pattern
of widespread misuse.
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8. Moreover, there has been a systemic failure of
public policy and on the part of the public
health authorities to control three key drivers of
incorrect usage; pricing, prescribing and
distribution. The professional fees paid to
prescribers and pharmacies now exceed the
ingredient cost of the drugs. The figures from
the prescriptions database suggest that the
good practice prescribing guidelines have had
little impact. Evidence for the lack of effective
controls on distribution is to be found in the
sheer quantities being prescribed, which
makes it easy to divert to the black market.
9. The public health authorities have failed to
develop a continuum of medical and non-
medical supports for those addicted to minor
tranquillisers and sedatives. Moreover, they
have failed to get primary care, mental health
and community service providers participating
in a joined up care and service model that
could ensure addiction is picked up quicker,
treated sooner and managed more fully, no
matter which setting the individual presents to.
10. Addiction Counsellors in the Mental Health
Service and Substance Misuse Counsellors in
the Drug Service appear to share the same
broad concerns about the misuse of minor
tranquillisers and sedatives. These dovetail
neatly with the health promotion perspective on
addiction. In summary, the chief concerns
relate to:
A Continued high levels of prescribing by
some doctors;
B Personal choices by some individuals to
use minor tranquillisers and sedatives
incorrectly, on a prescribed and/or an illicit
basis, often in a multi-substance mix.
C The failure of the health authorities and
professional regulatory agencies to be more
proactive in identifying and addressing
inappropriate prescribing and dispensing;
D The incentives in the drug refund schemes,
which do not reward or penalise good or
bad prescribing and dispensing;
E The ease with which significant quantities of
minor tranquillisers and sedatives,
especially Diazepam, are ‘disappearing’ to
the street because of lax controls on
prescribing and distribution.
11. The interviews with service providers
highlighted significant deficiencies in ensuring
that all individuals have equal access to the
same range of services regardless of the
setting in which they present. In particular, the
abstinence approach favoured by Mental
Health may not sit easily with the harm
reduction model in the Drug Service. 
In practical terms, this could mean that an
individual, who may be labelled as a ‘drug user’
and presents to the Drug Service with an
addiction to minor tranquillisers or sedatives, is
not guaranteed access to detoxification,
whereas they would likely get this service as
part of a multidisciplinary care package were
they to access the Mental Health Service
through a GP.
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Number of Individuals
1. Some 89,721 distinct individuals in counties
Galway, Mayo and Roscommon were
prescribed minor tranquillisers and sedatives
between 2000 and 2007.
2. Almost 80% of these individuals were people
who were entitled to see their doctor and to get
their prescriptions free of charge (GMS), while
the vast majority of the remaining 21% were
people who paid the doctor and pharmacist but
were entitled to claim a refund on the cost of
their prescriptions (DPS). 
3. About 42% were male and 58% female.
General Profile
1. The numbers of people prescribed minor
tranquillisers and sedatives in all three
schemes has increased year on year – up from
slightly less than 25,000 in 2000 to a little over
33,000 in 2007.
2. Looking at averages across the period:
a. Around 54% of those prescribed minor
tranquillisers and sedatives were over the
age of 65. As a general comparator, only
12.5% of the population of the three
counties was aged 65+ in 2006.
b. The percentage of males was 38%, and the
percentage of females 62%. As a general
comparator, the population of the region
was evenly split between males and
females in 2006
c. Some 49% were from Galway, 34% from
Mayo and 17% from Roscommon. As a
general comparator, the population
distribution was 56% in Galway, 30% in
Mayo and 14% in Roscommon in 2006.
d. The average percentages of people in the
GMS and DPS were 52% and 46%
respectively for the period from 2000 to
2007.
3. In summary, women, older people and people
on low incomes are over-represented in the
averages, while men and people on higher
incomes are correspondingly under-
represented.
Number of Prescriptions
1. The total number of prescriptions written in the
three counties increased every year between
2000 and 2007.
2. People aged 65 or more, who comprise just
12.5% of the population of the region, got close
to two-thirds of all prescriptions.
3. Women, who comprise around half the
population of the region, also got close to two-
thirds of all prescriptions.
4. Some 1.5 million prescriptions – were
reimbursed between 2000 and 2007. Almost
88% of prescriptions went to people with
medical cards, while almost all of the remaining
12% of prescriptions were for people in the
DPS.
a. Across all three schemes, the top five
drugs, measured in descending order of
number of prescriptions, were Temazepam,
Diazepam, Zopiclone, Alprazolam and
Bromazepam. 
i. In the GMS, the top five drugs were
Temazepam, Diazepam, Alprazolam,
Zopiclone and Bromazepam.
ii. Four of the top five in the GMS were also
in the top five of the DPS, albeit in
different rank order, with Bromazepam
displaced from fifth position by
Zolpidem, which joined Zopiclone as the
second and second most popular non-
benzodiazepine hypnotic on the list of
most prescribed minor tranquillisers and
sedatives.
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Drug Usage
1. The Benzodiazepine Committee used the
Defined Daily Dose measurement system to
arrive at a rough estimate of the proportion of
the population treated daily with minor
tranquillisers and sedatives. (It gave the
example that a figure of 10 DDDs per 1,000
inhabitants per day would indicate that the
amount used in terms of one normal adult dose
per day would be given to 1% of the population
on average). We followed the same approach
in this study.
2. In the GMS, usage, as measured in Defined
Daily Doses / 1,000 / Day of the scheme
population fell by 2% in 2001, a full year before
the good practice prescribing guidelines for
clinicians were published, but increased every
year except one thereafter: up 15% in 2002, up
7% in 2003, up 7% in 2004, up 4% in 2005,
down 2% in 2006, and finally, up 3% in 2007.
3. In 2000, around 7.5% of the GMS population of
the three counties were using minor
tranquillisers and sedatives. By 2007, this had
increased to slightly less than 10%. In other
words, the good practice guidelines had little or
no effect in the GMS and a pattern of increased
prescribing became more deeply embedded.
4. In the DPS, usage, as measured in Defined
Daily Doses / 1,000 / Day of the scheme
population decreased four years in a row (2001
to 2004) but fluctuated in both directions in the
following three years. The reductions were 7%,
13%, 10% and 1% between 2001 and 2004.
Usage increased by 20% in 2005, fell by 1% in
2006 and rose by 8% in 2007.
5. In 2000, around 1.5% of the DPS population of
the three counties were using minor
tranquillisers and sedatives. By 2007, this
number was largely unchanged, albeit that
some significant reductions were achieved in a
number of the intervening years. From this we
may conclude that the good practice
guidelines may have had some positive effect,
albeit in a context where usage in the DPS was
small to begin with, and much smaller by
contrast with the GMS.
6. The number of DDDs per 1,000 per day of the
GMS population has been a significant multiple
of the number of DDDs per 1,000 per day of the
DPS population in all years. The multiple was 5
in two years, 7 in four, 8 in one, and 9 in one
year. This suggests that people in the GMS get
from 5 to 9 times the number of DDDs as
people in the DPS. 
7. The quantity of doses per form i.e. the number
of DDDs per prescription form appears to be
well within the good practice guidelines. In the
GMS, the average of DDDs from 2000 to 2007
is 21.54 days supply; while the figure in the
DPS is slightly lower, at 20.08 days.
Long-Term Usage and Prescribing
1. However, in terms of those who are actually
being prescribed minor tranquillisers and
sedatives, as opposed to the numbers who are
estimated to be using them, there are serious
issues with regard to long term usage and long
term prescribing. We defined the former as the
number of individuals in the medical card and
the private schemes who are prescribed > 56
DDDs (two months supply or more) per year for
anywhere from two to eight consecutive years.
We defined long term prescribing as the
number of doctors who prescribe > 56 DDDs
(two months supply or more) per year of the
same drug to the same individual for anywhere
from two to eight consecutive years.
2. This analysis identified that there is a significant
number being prescribed minor tranquillisers
and sedatives for long periods - longer than the
maximum recommended times. Taking the
GMS, DPS and LTI together, a total of 15,935
people, or nearly 18% of all individuals, had
been prescribed minor tranquillisers and
sedatives for two months or more at least once
for up to eight consecutive years. Clearly this
goes far beyond the maximum recommended
period of a one-month, once-off prescription
favoured in the good practice guidelines. GMS
clients i.e. people in the state-funded scheme
account for almost nine out of ten of those
affected; and they outnumber those in the
private, pay-as-you-go scheme by a factor of
between 5 and 18 times.
3. This analysis also identified a significant
number of doctors prescribing to some patients
for protracted periods. The highest number
prescribing two months supply or more at least
once in consecutive years, was for two
consecutive years (389 GPs) and the lowest
number was for eight consecutive years (159
GPs). In all, there were 415 GPs who
prescribed in protracted fashion, as defined, at
least once during the period under study here.
Recommendations
1. The Health Service Executive, Medical Council
of Ireland and the Pharmaceutical Society of
Ireland should work closely and more
proactively together to identify and address
known or suspected cases of inappropriate
prescribing and dispensing.
2. Consideration should be given to making the
current good practice prescribing guidelines
binding on all prescribers.
3. Consideration should be given to moving minor
tranquillisers and sedatives into a higher
control schedule, so that prescribers must
endorse in their own hand-writing, the quantity
and dose on every prescription and
pharmacies are required to keep these drugs in
an appropriate storage place.
4. The HSE should take the lead in providing
simple, complete and accessible information,
so that individuals can make an informed
decision about whether to use or refuse 
these drugs.
5. Prescribers should have a particular
responsibility to use the power that flows from
their expertise, to level the playing field for
patients, so that those individuals are not at a
relative disadvantage through not being
properly informed, empowered and engaged to
weigh the costs and benefits of using 
or refusing these drugs. 
6. Courses in the practice of medicine and
pharmacy should include an increased
emphasis on good prescribing and dispensing
practices, so that professional awareness and
understanding of the risks and benefits of minor
tranquillisers and sedatives is maximised.
7. The HSE should make it a priority to develop a
joined-up care and service model straddling
primary care, mental health, community
services, and not-for-profit/voluntary service
providers, so that all those who seek treatment
for an addiction to minor tranquillisers and
sedatives have the same access to the same
range of medical and non-medical supports,
regardless of the setting they present in.
8. The NDTRS statistical reporting system should
be extended to include General Practitioners.
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Table 1 Number of Individuals; Scheme and Gender; GMR Region 2000-2007.
Table 2 Number of Patients: Age; GMR Region 2000-2007 
Table 3 Number of Patients: Gender; GMR Region 2000-2007
Age Year 2000 2001 2002 2003 2004 2005 2006 2007
< 15 466 380 311 260 195 163 154 141
15-24 219 249 325 454 542 632 728 980
25-44 2,344 2,867 3,159 3,492 3,769 4,005 4,406 5,369
45-64 6,607 7,350 8,158 8,466 9,077 9,684 10,513 11,613
65+ 15,279 15,876 15,901 15,781 15,771 15,830 15,338 15,264
Unlisted 22 12 4 2
Gender 2000 2001 2002 2003 2004 2005 2006 2007
Male 9,572 10,181 10,702 10,730 11,207 11,604 11,764 12,549
Female 15,296 16,478 17,111 17,677 18,113 18,680 19,351 20,797
Unlisted 69 63 53 46 34 30 28 23
Table 5 Number of Patients: County; GMR Region 2000-2007
County 2000 2001 2002 2003 2004 2005 2006 2007
Galway 11,975 13,021 13,496 13,813 14,219 14,649 15,238 16,480
Mayo 8,802 9,152 9,540 9,726 10,116 10,427 10,607 11,264
Roscommon 4,061 4,461 4,778 4,869 4,972 5,202 5,268 5,597
Unlisted 96 82 50 45 46 36 29 27
Table 4 Number of Patients: Scheme; GMR Region 2000-2007
Scheme 2000 2001 2002 2003 2004 2005 2006 2007
GMS 21,105 22,236 23,392 23,918 24,563 25,080 25,236 26,378
DPS 3,741 4,396 4,384 4,442 4,693 5,137 5,798 6,881
LTI 91 90 90 93 98 97 109 110
Scheme
GMS 70,486
DPS 18,992
LTI 243
Total 89,721
Gender
Male 37,522
Female 52,199
Total 89,721
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Table 6 Prescriptions: Total; GMR Region 2000-2007
Year
2000 150,944
2001 152,074
2002 175,095
2003 183,048
2004 194,978
2005 205,650
2006 213,469
2007 231,158
Total 1,506,416 
2000 2001 2002 2003 2004 2005 2006 2007 Total
GMS 133,065 131,460 154,134 162,061 172,670 180,827 185,884 198,173 1,318,274
DPS 17,262 20,011 20,394 20,396 21,723 24,216 26,924 32,350 183,276 
LTI 617 603 567 591 585 607 661 635 4,866
150,944 152,074 175,095 183,048 194,528 205,650 215,196 229,881 1,506,416
Age GMS DPS LTI Total
< 15 11,457 327 312 12,096
15-24 8,864 1,714 210 10,788
25-44 101,091 16,587 1,775 119,453
45-64 322,656 103,990 1,547 428,193
65+ 874,145 60,541 941 935,627
Unlisted 61 117 81 259
Total 1,318,274 183,276 4,866 1,506,416
Table 7 Prescriptions: Number by Age; GMR Region 2000-2007
Gender GMS DPS LTI Total
Male 471,120 66,574 1,323 539,017
Female 847,154 116,356 1,283 964,793
Unlisted 346 2,260 2,606
Total 1,318,274 183,276 4,866 1,506,416
Table 8 Prescriptions: Number by Gender; GMR Region 2000-2007
Table 10 Prescriptions Numbers by Scheme; GMR Region 2000-2007 
Table 9 Prescriptions: Number by County; GMR Region 2000-2007
County
Galway 710,887
Mayo 514,696
Roscommon 278,064
Unlisted 2,769
Total 1,506,416
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Table 11 Number of GMS, DPS and LTI Prescriptions and Top 5 Drugs in each scheme; Galway,
Mayo and Roscommon, 2000-2007
Number of Prescriptions Per Drug GMS DPS LTI Total
Alprazolam 161,298 35,014 40 196,352
Bromazepam 87,100 14,810 80 101,990
Brotizolam 10 10
Chlordiazepoxide 33,577 3,769 17 37,363
Clobazam 12,118 1,504 2,542 16,164
Diazepam 221,727 26,264 1,031 249,022
Flunitrazepam 32,352 3,522 35,874
Flurazepam 72,004 10,273 124 82,401
Loprazolam 1 1
Lorazepam 30,701 2,931 71 33,703
Lormetazepam 33,549 3,823 4 37,376
Medazepam 1 1
Midazolam 1,515 89 141 1,745
Nitrazepam 60,200 3,178 355 63,733
Potassium Clorazepate 9,593 1,567 28 11,188
Prazepam 8,286 1,909 2 10,197
Temazepam 286,420 19,752 67 306,239
Triazolam 24,388 3,150 7 27,545
Zaleplon 7,123 1,891 19 9,033
Zolpidem 78,946 17,415 38 96,399
Zopiclone 157,365 32,415 300 190,080
Total Prescriptions 1,318,274 183,276 4,866 1,506,416
Percentage of Prescriptions by Scheme 87.51% 12.17% 0.32% 100.00%
Top 5 Drugs by Number of Prescriptions
GMS DPS LTI Total
1. Temazepam 1. Alprazolam 1. Clobazam 1. Temazepam
2. Diazepam 2. Zopiclone 2. Diazepam 2. Diazepam
3. Alprazolam 3. Diazepam 3. Nitrazepam 3. Alprazolam
4. Zopiclone 4. Temazepam 4. Zopiclone 4. Zopiclone
5. Bromazepam 5. Zolpidem 5. Midazolam 5. Bromazepam
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2000 2001 2002 2003 2004 2005 2006 2007
Alprazolam 212,717 234,387 285,852 296,945 320,145 337,723 363,770 390,419
Bromazepam 120,693 111,322 115,385 112,685 111,264 113,324 111,175 112,836
Brotizolam 0 0 0 0 96 57 0 0
Chlordiazepoxide 58,291 51,302 60,888 65,755 66,624 64,042 38,803 66,378
Clobazam 0 0 47,701 46,138 50,688 48,959 47,331 52,190
Diazepam 508,270 486,144 520,122 520,073 549,955 558,276 551,567 583,806
Flunitrazepam 145,993 130,724 143,391 131,112 129,767 125,998 121,894 124,362
Flurazepam 191,737 183,360 210,779 213,917 214,821 216,507 208,494 214,565
Loprazolam 28 0 0 0 0 0 0 0
Lorazepam 94,160 90,296 94,987 101,960 97,754 87,183 85,650 94,867
Lormetazepam 110,828 98,153 115,475 119,286 116,529 115,332 106,637 105,002
Medazepam 50 0 0 0 0 0 0 0
Midazolam 1,466 1,473 709 983 2,097 2,011 3,453 2,758
Nitrazepam 308,342 273,770 276,427 267,717 255,402 238,160 219,058 199,175
Pot Clorazepate 37,138 30,535 28,328 26,513 25,043 23,535 7,345 461
Prazepam 14,596 13,014 14,014 13,484 12,879 13,370 12,693 13,283
Temazepam 695,387 690,473 793,563 818,573 829,578 815,156 796,849 798,860
Triazolam 86,957 75,601 89,115 93,353 90,745 90,680 94,470 97,353
Zaleplon 14,963 24,587 22,455 19,128 15,935 14,354 10,167 8,671
Zolpidem 71,713 83,472 135,076 190,440 247,738 305,572 343,080 399,191
Zopiclone 282,030 305,022 414,423 488,104 573,565 659,777 753,257 898,935
Total DDDs 2,955,357 2,883,634 3,368,686 3,526,163 3,710,621 3,830,013 3,875,692 4,163,110
DDDs / 1,000 / Day 74.24 73.06 83.79 89.48 95.51 99.00 96.67 99.32
Frequency 133,065 131,460 154,134 162,061 172,670 180,827 185,884 198,173
Quantity Per Form 22.21 21.94 21.86 21.76 21.49 21.18 20.85 21.01
Table 12 Usage of Minor Tranquillisers and Sedatives: DDDs, Frequency of Prescriptions and
Quantity Per Form; GMS (Medical Card) Adult Population; GMR Region 2000-2007 
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2000 2001 2002 2003 2004 2005 2006 2007
Alprazolam 41,849 55,156 59,468 57,861 61,071 66,181 73,214 84,476
Bromazepam 14,915 17,052 18,851 17,850 18,440 20,722 19,674 22,327
Chlordiazepoxide 5,282 5,490 7,541 7,531 6,882 6,676 5,963 7,502
Clobazam 4,015 4,674 4,285 3,790 2,902 2,722 3,317 4,433
Diazepam 41,156 45,719 45,601 42,394 47,481 51,680 57,674 64,710
Flunitrazepam 13,965 15,566 14,947 12,595 14,390 14,536 10,794 14,330
Flurazepam 26,943 32,673 28,809 26,365 27,674 28,848 27,751 30,379
Lorazepam 7,248 8,550 6,245 6,344 6,434 5,721 6,814 10,964
Lormetazepam 13,670 15,187 12,642 11,455 10,929 10,593 13,466 15,257
Midazolam 293 55 17 57 57 69 50 71
Nitrazepam 21,946 19,565 13,543 13,098 11,422 10,258 9,696 11,074
Pot Clorazepate 4,592 5,003 4,839 4,195 4,227 3,481 1,160 23
Prazepam 3,374 3,676 2,684 3,932 3,873 4,249 4,398 3,246
Temazepam 58,418 60,611 55,146 47,268 46,729 45,683 52,062 62,095
Triazolam 11,655 13,092 10,826 10,684 11,988 14,313 14,076 14,630
Zaleplon 3,701 7,914 5,885 3,941 3,880 4,375 4,432 3,689
Zolpidem 15,920 21,609 29,101 41,228 51,540 61,893 80,402 100,719
Zopiclone 70,281 89,941 92,827 96,340 107,612 123,487 143,470 169,090
Total DDDs 359,222 421,533 413,253 406,926 437,529 475,485 528,410 619,013
DDDs / 1,000 / Day 15.41 14.33 12.44 11.21 11.07 13.28 13.13 14.17
Frequency 17,262 20,011 20,394 20,396 21,723 24,216 26,924 32,350
Quantity Per Form 20.81 21.07 20.26 19.95 20.14 19.64 19.63 19.13
Table 13 Usage of Minor Tranquillisers and Sedatives: DDDs, Frequency of Prescriptions and
Quantity Per Form; DPS ('Private') Adult Population; GMR Region 2000-2007
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Long Term Prescribing 2 Years 3 Years 4 Years 5 Years 6 Years 7 Years 8 Years
Number of Doctors 390 270 233 213 189 165 160 
Table 15 Number of Doctors who prescribe > 56 DDDs (two months supply or more) to the same
patient for two to eight consecutive years, in the GMS Scheme.
Long Term Usage 2 Years 3 Years 4 Years 5 Years 6 Years 7 Years 8 Years Total
GMS 4,141 2,445 1,643 1,276 1,036 903 2,403 13,847
DPS 891 383 237 158 136 84 134 2,023
LTI 10 10 7 13 4 4 17 65
Total 5,042 2,838 1,887 1,447 1,176 991 2,554 15,935
Table 14 Number of Patients who have received > 56 DDDs (two months supply or more) per year
for two to eight consecutive years in the GMS, DPS and LTI Schemes.
56
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
G
M
S
D
ru
g 
C
os
t
6,
21
0,
31
5
6,
83
7,
33
3
8,
28
6,
53
8
8,
99
4,
98
2
9,
66
0,
75
3
10
,1
69
,9
56
10
,6
04
,2
63
10
,3
16
,8
32
Pr
of
es
si
on
al
 F
ee
4,
31
1,
29
8
5,
12
3,
60
7
6,
17
1,
47
0
7,
28
0,
74
5
8,
27
6,
61
5
8,
69
8,
81
0
9,
93
1,
77
9
10
,6
96
,0
37
D
P
S
D
ru
g 
C
os
t
1,
75
3,
76
9
2,
18
5,
24
4
2,
24
1,
87
5
2,
24
4,
39
0
2,
31
9,
52
2
2,
37
8,
72
4
2,
52
9,
35
6
2,
47
9,
67
1
Pr
of
es
si
on
al
 F
ee
1,
63
0,
90
2
2,
10
9,
51
4
2,
19
1,
05
1
2,
19
7,
54
6
2,
27
0,
81
0
2,
32
1,
72
3
2,
59
4,
88
3
2,
72
9,
43
3
LT
I
D
ru
g 
C
os
t
55
,2
48
56
,6
67
59
,0
89
63
,6
85
64
,1
11
93
,0
23
10
8,
15
2
11
3,
58
5
Pr
of
es
si
on
al
 F
ee
50
,1
13
54
,0
28
56
,5
33
59
,5
63
60
,8
55
77
,3
55
88
,8
92
91
,9
89
To
ta
l (
Ir
el
an
d
)
€1
4,
01
1,
64
5
€1
6,
36
6,
39
3
€1
9,
00
6,
55
6
€2
0,
84
0,
91
1
€2
2,
65
2,
66
6
€2
3,
73
9,
59
1
€2
5,
85
7,
32
5
€2
6,
42
7,
54
7
To
ta
l C
o
st
s
€1
68
,9
02
,6
34
G
M
S
 D
ru
g
€7
1,
08
0,
97
2
G
M
S
 F
ee
€6
0,
49
0,
36
1
D
P
S
 D
ru
g
€1
8,
13
2,
55
1
D
P
S
 F
ee
€1
8,
04
5,
86
2
LT
I 
D
ru
g
€6
13
,5
60
LT
I 
F
ee
€5
39
,3
28
To
ta
l
€1
68
,9
02
,6
34
Ta
b
le
 1
6 
P
u
b
lic
 E
xp
en
d
it
u
re
 o
n
 M
in
o
r T
ra
n
q
u
ill
is
er
s 
an
d
 S
ed
at
iv
es
;
G
M
S
,D
P
 a
n
d
 L
T
I S
ch
em
es
;
Ir
el
an
d
 2
00
0-
20
07
.
57
Ta
bl
es
N
um
be
rs
 E
lig
ib
le
 (
G
M
R
 R
eg
io
n)
G
M
S
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
A
ve
ra
ge
%
 o
f T
ot
al
13
9,
05
3
14
2,
28
7
13
8,
32
9
13
6,
08
9
13
4,
15
8
13
3,
58
2
13
8,
68
0
14
4,
89
7
13
8,
38
4
51
.6
8%
D
PS
84
,9
20
10
4,
26
6
11
8,
89
3
12
5,
63
2
13
5,
82
4
13
0,
11
9
14
0,
83
4
15
2,
06
8
12
4,
07
0
46
.3
3%
LT
I
5,
25
7
5,
39
6
5,
85
7
6,
27
3
4,
13
3
4,
65
7
5,
22
0
5,
89
3
5,
33
6
1.
99
%
To
ta
l
22
9,
23
0
25
1,
94
9
26
3,
07
9
26
7,
99
4
27
4,
11
5
26
8,
35
8
28
4,
73
4
30
2,
85
8
26
7,
79
0
10
0.
00
%
N
um
be
rs
 E
lig
ib
le
 (
Ire
la
nd
)
G
M
S
20
00
20
01
20
02
20
03
20
04
20
05
20
06
20
07
A
ve
ra
ge
%
 o
f T
ot
al
1,
14
8,
05
5
1,
19
9,
45
4
1,
16
8,
74
5
1,
15
8,
14
3
1,
14
8,
91
4
1,
15
5,
72
7
1,
22
1,
69
5
1,
27
6,
17
8
1,
18
4,
61
4
44
.8
7%
D
PS
94
2,
19
3
1,
15
6,
83
6
1,
31
9,
39
5
1,
39
6,
81
3
1,
46
9,
25
1
1,
47
8,
65
0
1,
52
5,
65
7
1,
58
3,
73
8
1,
35
9,
06
7
51
.4
8%
LT
I
82
,6
19
87
,9
88
92
,7
45
97
,1
84
93
,5
04
99
,2
80
10
6,
30
7
11
2,
58
0
96
,5
26
3.
66
%
To
ta
l
2,
17
2,
86
7
2,
44
4,
27
8
2,
58
0,
88
5
2,
65
2,
14
0
2,
71
1,
66
9
2,
73
3,
65
7
2,
85
3,
65
9
2,
97
2,
49
6
2,
64
0,
20
6
10
0.
00
%
%
 Ir
is
h 
Po
pu
la
tio
n
in
 T
hr
ee
 S
ch
em
es
57
.3
8
63
.6
6
66
.1
8
67
.7
1
67
.0
5
68
.5
3
67
.3
9
70
.1
1
Ta
b
le
 1
7 
N
u
m
b
er
 o
f 
P
eo
p
le
 E
lig
ib
le
 f
o
r 
P
ri
n
ci
p
al
 C
o
m
m
u
n
it
y 
D
ru
g
 R
ef
u
n
d
 S
ch
em
es
;
G
M
R
 R
eg
io
n
 a
n
d
 Ir
el
an
d
 2
00
0-
20
07
.
58
County
Galway 231,670
Mayo 123,839
Roscommon 58,768
Total 414,277
Gender
Males 209,290 51%
Females 204,987 49%
Total 414,277
Age Galway Mayo Roscommon
0-14 46,046 25,409 11,977
15-24 37,886 16,430 7,438
25-44 72,859 33,356 16,165
45-64 49,371 30,782 14,473
65+ 25,508 17,862 8,715
Total 231,670 123,839 58,768
Table 18 Population GMR Region (Census 2006).
Appendix 2
WHO DDD Values
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Appendix 2: Minor Tranquillisers & Sedatives
Generic Drug Names & Defined Daily Dose Values
Generic / Approved Name W.H.O. DDD Value61
Alprazolam 1mg
Bromazepam 10mg
Brotizolam 0.25mg
Chlordiazepoxide 30mg (or 50mg by Injection)
Clobazam 20mg
Clorazepate 20mg
Diazepam 10mg 
Flunitrazepam 1mg
Flurazepam 30mg
Loprazolam 1mg
Lorazepam 2.5mg
Lormetazepam 1mg
Medazepam 20mg
Midazolam 15mg
Nitrazepam 5mg
Prazepam 30mg
Temazepam 20mg
Triazolam 0.25mg (or 0.2mg under tongue)
Zaleplon 10mg
Zolpidem 10mg
Zopiclone 7.5mg
60
61 DDDs from British National Formulary and World Health Organisation’s DDD Index.
Appendix 3
A Case Study of Codeine Addiction
61
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Although this research was concerned with the
addictive potential of minor tranquillisers and
sedatives, we became aware during the study that
concern is rising among healthcare professionals
about the increasing numbers of people who may
be misusing over-the-counter combination
products containing Codeine, an opioid drug used
for the relief of mild to moderate pain.
In the Focus Group, there was one individual who
spoke about his own personal battle with Codeine
addiction. His is a story that echoes the
experiences of others who have battled an
addiction to minor tranquillisers and sedatives. It
also underlines that Codeine addiction is a
significant hidden problem that, at the least, merits
further, detailed analysis.
John’s Story
John is married and recovering from an addiction
to Codeine. After taking it for a hangover, he
found it also gave a feeling of euphoria. He
preferred Nurofen Plus, which he discovered had
"50% more of a [Codeine] hit" than a rival product,
Solpadeine.
John described a typical routine in the following
way: “A general day in my life was get up in the morning,
take 14-16 tablets, around 10am take another 12,
lunchtime might take another 12, and then in the evening
take another 12 just before I got in the door, just to try and
be in good form for everyone … I would be ‘up’ after 10
minutes. That lasted for maybe an hour-and-a-half. Then
I knew it was time to take more tablets.”
His approach was to travel to a particular town,
make as many separate visits as he could to every
pharmacy, buying a pack of Nurofen Plus at every
visit. He would then leave a gap of six to eight
weeks before visiting the same town again so as
not to arouse suspicion.
John recalls how he would often walk past a
pharmacy he had already called into, just to see if
the person who had served him was still there; if
they were, that was his “cue not to go in” and risk
being “barred”.
He says he was careful not to ask for more than the
maximum amount the pharmacy was legally
permitted to sell; again taking care to avoid
detection. If possible, he would try and get all the
Codeine he needed for three days in the one town.
He might then drive to the next town for another
three days supply. He found himself making mental
notes of all the places he had visited, trying to
remember not to go back for a while.
He mentions travelling as far away as Sligo, Cavan,
Portlaoise and Galway to buy Codeine: “With the
amounts I was using – 21 boxes minimum a week – you
couldn’t go back immediately [to one chemist] again
because of the shame, the embarrassment of being refused
tablets because you were here before.” Though he feared
being refused, he never was.
John recalls the extent to which he normalised his
addiction: he “knew the cost of getting the drugs and
knew the cost of getting to get them”; he often spent
“thirty, forty, fifty euro” in a pharmacy buying
products he didn’t need, just so he could ask for
Nurofen Plus “by the way”.
He remembers the night before he left for a short
holiday to a country where he knew there were
restrictions on sales of over the counter medicines.
Satisfied that he had bought enough beforehand to
last the whole trip, but worried that all could be lost
if his luggage went astray, and conscious that the
presence of so many packs of the one painkiller in
his hand luggage would prompt questions if he
was searched, he and his wife spent an hour
pushing the tablets from their blisters into large
jars.
Eventually his wife gave him an ultimatum, which
prompted him to get help. Over several months, he
reduced to between 12 and 14 tablets a day and
then he “jumped”. He says the withdrawal
symptoms were severe and included sweats,
anxiety, and an inability to sleep.
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John believes Codeine should be prescription-
only: “I would go through a wall to get my Codeine. I
would go anywhere. I would cancel anything. Whether it
was family or business. Because I had to have it. I would
have done crime to get it in the end, no problem. Codeine
is that strong.”
That desire for greater control over the supply of
Codeine has recently been echoed by Dr John
O’Connor, Clinical Director of the Drug Treatment
Centre Board, who has published statistics
showing that the number on Codeine rehabilitation
programmes in Ireland has more than doubled in
the space of two years.
According to the figures, 52 Codeine addicts were
treated in rehab in 2006, up from 42 in 2004 and
from 22 in 2004. The DTCB has found addicts are
most likely to be middle-aged, middle-class
women looking for a stress reliever from their daily
lives.
Separately it has been reported that sales of
Solpadeine, a leading brand, rose from €18m to
€21m from 2006 to 2007.62
62 Codeine addicts seeking rehab, Irish Independent, 18 May 2008.
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